
Jack Ansell, Jack Hirsh, Elaine Hylek, Alan Jacobson, Mark Crowther and Gualtiero Palareti

Chest 2008;133;160-198
DOI 10.1378/chest.08-0670

The online version of this article, along with updated information and services can be found online on the World Wide Web at: http://chestjournal.org/cgi/content/abstract/133/6_suppl/160S

CHEST is the official journal of the American College of Chest Physicians. It has been published monthly since 1935. Copyright 2007 by the American College of Chest Physicians, 3300 Dundee Road, Northbrook IL 60062. All rights reserved. No part of this article or PDF may be reproduced or distributed without the prior written permission of the copyright holder (http://www.chestjournal.org/misc/reprints.shtml). ISSN: 0012-3692.
Pharmacology and Management of the Vitamin K Antagonists*

American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th Edition)

Jack Ansell, MD; Jack Hirsh, MD; Elaine Hylek, MD, MPH; Alan Jacobson, MD; Mark Crouther, MD; and Gualtiero Palareti, MD

This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). It describes the antithrombotic effect of the VKAs, the monitoring of anticoagulation intensity, and the clinical applications of VKA therapy and provides specific management recommendations. Grade 1 recommendations are strong and indicate that the benefits do or do not outweigh the risks, burdens, and costs. Grade 2 recommendations suggest that the individual patient’s values may lead to different choices. (For a full understanding of the grading, see the “Grades of Recommendation” chapter by Guyatt et al, CHEST 2008; 133:123S–131S.)

Among the key recommendations in this article are the following: for dosing of VKAs, we recommend the initiation of oral anticoagulation therapy, with doses between 5 mg and 10 mg for the first 1 or 2 days for most individuals, with subsequent dosing based on the international normalized ratio (INR) response (Grade 1B); we suggest against pharmacogenetic-based dosing until randomized data indicate that it is beneficial (Grade 2C); and in elderly and other patient subgroups who are debilitated or malnourished, we recommend a starting dose of ≤ 5 mg (Grade 1C). The article also includes several specific recommendations for the management of patients with nontherapeutic INRs, with INRs above the therapeutic range, and with bleeding whether the INR is therapeutic or elevated. For the use of vitamin K to reverse a mildly elevated INR, we recommend oral rather than subcutaneous administration (Grade 1A). For patients with life-threatening bleeding or intracranial hemorrhage, we recommend the use of prothrombin complex concentrates or recombinant factor VIIa to immediately reverse the INR (Grade 1C). For most patients who have a lupus inhibitor, we recommend a therapeutic target INR of 2.5 (range, 2.0 to 3.0) [Grade 1A]. We recommend that physicians who manage oral anticoagulation therapy do so in a systematic and coordinated fashion, incorporating patient education, systematic INR testing, tracking, follow-up, and good patient communication of results and dose adjustments [Grade 1B]. In patients who are suitably selected and trained, patient self-testing or patient self-management of dosing are effective alternative treatment models that result in improved quality of anticoagulation management, with greater time in the therapeutic range and fewer adverse events. Patient self-monitoring or self-management, however, is a choice made by patients and physicians that depends on many factors. We suggest that such therapeutic management be implemented where suitable (Grade 2B). (CHEST 2008; 133:160S–198S)

Key words: anticoagulation; pharmacogenetics; pharmacology; quality of care; vitamin K antagonists; warfarin

Abbreviations: AMS = anticoagulation management service; CHF = congestive heart failure; CI = confidence interval; DVT = deep vein thrombosis; HR = hazard ratio; INR = international normalized ratio; ISI = international sensitivity index; NSAID = nonsteroidal antiinflammatory drug; OR = odds ratio; PCC = prothrombin complex concentrate; POC = point of care; PSM = patient self-management; PST = patient self-testing; PT = prothrombin time; SNP = single nucleotide polymorphism; TTR = time in the therapeutic range; UC = usual care; VKA = vitamin K antagonist; VKOR = vitamin K oxide reductase; WHO = World Health Organization
Summary of Recommendations

2.1 Initiation and Maintenance Dosing

2.1.1. In patients beginning vitamin K antagonist (VKA) therapy, we recommend the initiation of oral anticoagulation with doses between 5 mg and 10 mg for the first 1 or 2 days for most individuals, with subsequent dosing based on the international normalized ratio (INR) response (Grade 1B). At the present time, for patients beginning VKA therapy without evidence from randomized trials, we suggest against the use of pharmacogenetic-based initial dosing to individualize warfarin dosing (Grade 2C).

2.2 Initiation of Anticoagulation in Elderly or Other Populations

2.2.1. In elderly patients or patients who are debilitated, are malnourished, have congestive heart failure (CHF), have liver disease, have had recent major surgery, or are taking medications known to increase sensitivity to warfarin (eg, amiodarone), we recommend the use of a starting dose of ≤ 5 mg (Grade 1C) with subsequent dosing based on the INR response.

2.3 Frequency of Monitoring

2.3.1. In patients beginning VKA therapy, we suggest that INR monitoring be started after the initial two or three doses of oral anticoagulation therapy (Grade 2C).

2.3.2. For patients who are receiving a stable dose of oral anticoagulants, we suggest monitoring at an interval of no longer than every 4 weeks (Grade 2C).

2.4 Management of Nontherapeutic INRs

2.4.1. For patients with INRs above the therapeutic range but < 5.0 and with no significant bleeding, we recommend lowering the dose or omitting a dose, monitoring more frequently, and resuming therapy at an appropriately adjusted dose when the INR is at a therapeutic level. If only minimally above therapeutic range or associated with a transient causative factor, no dose reduction may be required (all Grade 1C).

2.4.2. For patients with INRs of ≥ 5.0 but < 9.0 and no significant bleeding, we recommend omitting the next one or two doses, monitoring more frequently, and resuming therapy at an appropriately adjusted dose when the INR is at a therapeutic level (Grade 1C). Alternatively, we suggest omitting a dose and administering vitamin K (1 to 2.5 mg) orally, particularly if the patient is at increased risk of bleeding (Grade 2A). If more rapid reversal is required because the patient requires urgent surgery, we suggest vitamin K (≤ 5 mg) orally, with the expectation that a reduction of the INR will occur in 24 h. If the INR is still high, we suggest additional vitamin K (1 to 2 mg) orally (Grade 2C).

2.4.3. For patients with INRs ≥ 9.0 and no significant bleeding, we recommend holding warfarin therapy and administering a higher dose of vitamin K (2.5 to 5 mg) orally, with the expectation that the INR will be reduced substantially in 24 to 48 h (Grade 1B). Clinicians should monitor the INR more frequently, administer additional vitamin K if necessary, and resume therapy at an appropriately adjusted dose when the INR reaches the therapeutic range.

2.4.4. In patients with serious bleeding and elevated INR, regardless of the magnitude of the elevation, we recommend holding warfarin therapy and giving vitamin K (10 mg) by slow IV infusion supplemented with fresh frozen plasma, prothrombin complex concentrate (PCC), or recombinant factor VIIa, depending on the urgency of the situation. We recommend repeating vitamin K administration every 12 h for persistent INR elevation (all Grade 1C).

2.4.5. In patients with life-threatening bleeding (eg, intracranial hemorrhage) and elevated INR, regardless of the magnitude of the elevation, we recommend holding warfarin therapy and administering fresh frozen plasma, PCC, or recombinant factor VIIa supplemented with vitamin K, 10 mg by slow IV infusion, repeated, if necessary, depending on the INR (Grade 1C).

2.4.6. In patients with mild to moderately elevated INRs without major bleeding, we recommend that when vitamin K is to be given, it be administered orally rather than subcutaneously (Grade 1A).
2.5 Management of Variable INRs

2.5.1. For patients receiving long-term warfarin therapy with a variable INR response not attributable to any of the usual known causes for instability, we suggest a trial of daily low-dose oral vitamin K (100 to 200 μg), with close monitoring of the INR and warfarin dose adjustment to counter an initial lowering of the INR in response to vitamin K (Grade 2B).

2.6 Management of INRs in the Antiphospholipid Syndrome

2.6.1. In patients who have a lupus inhibitor, who have no additional risk factors, and who have no lack of response to therapy, we recommend a therapeutic target INR of 2.5 (INR range, 2.0 to 3.0) [Grade 1A]. In patients who have recurrent thromboembolic events with a therapeutic INR or other additional risk factors for thromboembolic events, we suggest a target INR of 3.0 (INR range, 2.5 to 3.5) [Grade 2C].

4.1 Optimal Management of VKA Therapy

4.1.1. For health-care providers who manage oral anticoagulation therapy, we recommend that they do so in a systematic and coordinated fashion, incorporating patient education, systematic INR testing, tracking, follow-up, and good patient communication of results and dosing decisions as occurs in an anticoagulation management service (AMS) [Grade 1B].

4.3 Patient Self-Testing and Patient Self-Management

4.3.1. Patient self-management (PSM) is a choice made by patients and health-care providers that depends on many factors. In patients who are suitably selected and trained, patient self-testing or PSM is an effective alternative treatment model. We suggest that such therapeutic management be implemented where suitable (Grade 2B).

The coumarins or vitamin K antagonists (VKAs) have been the mainstay of oral anticoagulant therapy for more than 60 years. Their effectiveness has been established by well-designed clinical trials for the primary and secondary prevention of venous thromboembolism, for the prevention of systemic embolism in patients with prosthetic heart valves or atrial fibrillation, as an adjunct in the prophylaxis of systemic embolism after myocardial infarction, and for reducing the risk of recurrent myocardial infarction. VKAs are challenging to use in clinical practice for the following reasons: (1) they have a narrow therapeutic window; (2) they exhibit considerable variability in dose response among patients due to genetic and other factors; (3) they are subject to interactions with drugs and diet; (4) their laboratory control is difficult to standardize; and (5) maintenance of a therapeutic level of anticoagulation requires a good understanding of the pharmacokinetics and pharmacodynamics of warfarin and good patient communication. Because warfarin is the most commonly used VKA worldwide, we will use it interchangeably with VKA throughout this article.

1.0 Pharmacology and Monitoring of VKAs

The VKAs produce their anticoagulant effect by interfering with the cyclic interconversion of vitamin K and its 2,3 epoxide (vitamin K epoxide), thereby modulating the γ-carboxylation of glutamate residues (Gla) on the N-terminal regions of vitamin K-dependent proteins1–7 (Fig 1). The vitamin K-dependent coagulation factors II, VII, IX, and X require γ-carboxylation for their procoagulant activity, and treatment with VKAs results in the hepatic production of partially carboxylated and decarboxylated proteins with reduced coagulant activity.8,9 Carboxylation is required for a calcium-dependent conformational change in coagulation proteins10–12 that promotes binding to cofactors on phospholipid surfaces. In addition, the VKAs inhibit carboxylation of the regulatory anticoagulant proteins C, S, and Z and thereby have the potential to be procoagulant.13 Under most circumstances, however, the anticoagulant effect of the VKAs is dominant. Carboxylation requires the reduced form of vitamin K (VKH2), a γ-glutamyl carboxylase, molecular oxygen, and carbon dioxide. Vitamin K epoxide can be reused by reduction to VKH2. The oxidation-reduction reaction involves a reductase pair. The first, vitamin K epoxide reductase, is sensitive to VKA, whereas vitamin K reductase is less sensitive.1–3 Therefore, the anticoagulant effect of the VKAs can be overcome by low doses of vitamin K (phytonadione) [Fig 1]. Patients treated with large doses of vitamin K can become resistant to warfarin for up to 1 week or more because the vitamin K accumulating in the liver is available to the VKA-insensitive reductase.

The VKAs also interfere with the carboxylation of Gla proteins that are synthesized in bone.14–17 Although these effects contribute to fetal bone abnormalities when mothers are treated with a VKA during pregnancy, it is unclear how they might affect children. Two uncontrolled cohort studies described...
reduced bone density in children on warfarin for > 1 year, but the role of the underlying disorders in reducing bone density remains unclear.20

1.1 Pharmacokinetics and Pharmacodynamics of Warfarin

Warfarin is the most common VKA in clinical use. It is a racemic mixture of two optically active isomers, the R and S enantiomers. Warfarin is highly water soluble, rapidly absorbed from the GI tract, has high bioavailability,21,22 and reaches maximal blood concentrations about 90 min after oral administration.21,23 Racemic warfarin has a half-life of 36 to 42 h24 (R-warfarin, 45 h; S-warfarin, 29 h); circulates bound to plasma proteins (mainly albumin); and accumulates in the liver, where the two enantiomers are metabolically transformed by different pathways (Fig 1).24 The S enantiomer of warfarin (2.7 to 3.8 times more potent than the R enantiomer) is metabolized primarily by the CYP2C9 enzyme of the cytochrome P450 system.25 The less potent R enantiomer is metabolized primarily by two cytochrome enzymes, 1A2 and 3A4. The relationship between the dose of warfarin and the response is modified by genetic and environmental factors that can influence the absorption of warfarin, its pharmacokinetics, and its pharmacodynamics.

Like warfarin, acenocoumarol and phenprocoumon also exist as optical isomers but with different stereochemical characteristics. R-acenocoumarol has an elimination half-life of 9 h; is primarily metabolized by CYP2C9 and CYP2C19; and is more potent than S-acenocoumarol due to faster clearance of S-acenocoumarol, which has an elimination half-life of 0.5 h and is primarily metabolized by CYP2C9.26 Phenprocoumon is a much longer-acting agent, with both the R- and the S-isomers having elimination half-lives of 5.5 days. Both are metabolized by CYP2C9, and S-phenprocoumon is 1.5 to 2.5 times more potent than R-phenprocoumon.27

Superwarfarin rodenticides are commonly used in the United States, and most contain brodifacoum, a
4-hydroxycoumarin with high lipid solubility and an elimination half-life of 24 days. In cases of accidental or intentional brodifacoum poisoning, the principal treatment is vitamin K, with repeated doses given anywhere from daily to every few days to counteract the long half-life of brodifacoum.28,29 For patients who are actively bleeding, immediate reversal can be achieved with factor concentrates, such as prothrombin complex concentrates (PCCs) or recombinant factor VIIa along with repeated daily administration of vitamin K.30

1.1.1 Genetic Factors

There are a number of mutations in the gene coding for the cytochrome P450 2C9 hepatic microsomal enzyme, which is responsible for the oxidative metabolism of the more potent warfarin S enantiomer, and these mutations will alter the pharmacokinetics of warfarin. The most common and best documented alleles, designated 2C9*2 or 2C9*3 to differentiate it from the wild type, 2C9*1, are associated with an impaired ability to metabolize S-warfarin, resulting in an increased S-warfarin elimination half-life. Mutations in this gene are independently responsible for the reduced warfarin requirements seen in individuals with one or more combinations of these polymorphisms (Table 1).24,31–35 Several investigations have shown that these mutations, as well as others,34,39,40 also are associated with an increase in adverse clinical outcomes that also occur with the use of acenocoumarol but not with phenprocoumon.33,52

The target for warfarin’s inhibitory effect on the vitamin K cycle is the vitamin K oxide reductase (VKOR) enzyme first described in 1974. The gene coding for the VKOR protein was recently identified and found to be located on the short arm of chromosome 16.44,45 The gene encodes for several isoforms of the protein that collectively are termed the VKOR complex 1 (VKORC1). Subsequently, mutations in this gene have been identified, leading to enzymes with varying sensitivities to inhibition by warfarin,45,46–50 thereby affecting the pharmacodynamics of warfarin. These mutations are likely to be the cause of hereditary warfarin resistance in some individuals.50 The mutations occur with differing frequencies in various ethnic populations and account, in part, for the difference in warfarin doses required to maintain a therapeutic international normalized ratio (INR).35,46–48,51 (Table 1).

Another genetic mutation that affects the pharmacodynamics of warfarin is in the factor IX propeptide. It causes selective reduction in factor IX during treatment with coumarin drugs without excessive prolongation of the prothrombin time (PT).33 Factor IX activity decreases to about 1 to 3% of normal, whereas levels of other vitamin K-dependent coagulation factors decrease to 30 to 40% of normal. Two distinct missense mutations involving the propeptide coding region have been described. They are estimated to occur in <1.5% of the population and are expressed as selectively increased sensitivity to the VKA-mediated reduction of factor IX activity.52 This selective marked reduction in factor IX activity has been reported to increase the risk of bleeding during anticoagulant therapy, and management of such rare patients can be difficult.53

| Table 1—Observed Frequency of CYP2C9 and VKOR Variants Among Various Ethnic Groups (Section 1.1.1) |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| CYP2C9 genetic alleles | CYP2C9*1 Arg144/Ile359, % | CYP2C9*2 Cys144/Ile359, % | CYP2C9*3 Arg144/Leu351, % | CYP2C9*4 Arg144/Thr359, % | CYP2C9*5 Arg144/Glu360, % |
| Ethnic group | | | | | |
| White | 79-86 | 8-19.1 | 6-10 | ND | ND |
| Indigenous Canadian | 91 | 3 | 6 | ND | ND |
| African American | 98.5 | 1-3.6 | 0.5-1.5 | ND | 2.3 |
| Asian | 95-98.3 | 0 | 1.7-5 | 0-1.6% | 0 |

<table>
<thead>
<tr>
<th>VKORC genetic Haplotype</th>
<th>VKORC genetic Sequence‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>H1 CCGATCTCTCG</td>
<td>H7 TCGGTCCGCGA</td>
</tr>
<tr>
<td>H2 CCGAGCTCTCG</td>
<td>H8 TAGGTCCGCGA</td>
</tr>
<tr>
<td>H9 TAGGTTCGGC</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ethnic group, %</th>
<th>H1 and H2 represent warfarin-sensitive haplotype. H7, H8, and H9 represent warfarin-resistant haplotype.</th>
</tr>
</thead>
<tbody>
<tr>
<td>European</td>
<td>37</td>
</tr>
<tr>
<td>African</td>
<td>14</td>
</tr>
<tr>
<td>Asian</td>
<td>89</td>
</tr>
</tbody>
</table>

*aCYP2C9 and VKORC data from Wittkowsky and Rieder et al. ND = not determined.
†CYP2C9*2, *3, *4, and *5 represent genetic polymorphisms of the wild-type enzyme. CYP2C9*1.
‡H1 and H2 represent warfarin-sensitive haplotype. H7, H8, and H9 represent warfarin-resistant haplotype.
1.1.2 Environmental Factors and Drug Interactions

Environmental factors such as drugs, diet, and various disease states can alter the pharmacokinetics of warfarin. Consequently, the INR should be measured more frequently than the usual 4-week interval when virtually any drug, dietary supplement, or herbal medicine is added or withdrawn from the regimen of a patient treated with warfarin. Drugs such as cholestyramine can reduce the anticoagulant effect of warfarin by reducing its absorption. Other drugs potentiate the anticoagulant effect of warfarin by inhibiting its clearance, whereas some drugs may inhibit the anticoagulant effect by enhancing its clearance. These latter effects may be through stereoselective or nonselective pathways. (Stereoactive interactions may affect the oxidative metabolism of either the S enantiomer or R enantiomer of warfarin.) Table 2 provides a comprehensive list of drugs that potentiate, inhibit, or have no effect on the anticoagulant effect of warfarin. A major problem with the literature on this topic is that many reports are single case studies and not well documented. Thus, the drugs categorized in Table 2 are listed by their probability of causation based on the quality of documentation as assessed by Holbrook et al in their systematic review.

The inhibition of S-warfarin metabolism is more important clinically because this enantiomer is five times more potent than the R enantiomer as a VKA. Phenylbutazone, phenylpirazone, metronidazole, trimethoprim-sulfamethoxazole, inhibit the clearance of S-warfarin, and each potentiates the effect of warfarin on the PT. In contrast, drugs such as cimetidine and omeprazole, which inhibit the clearance of the R-isomer, potentiate the PT only modestly in patients who have been treated with warfarin. Amiodarone is a potent inhibitor of the metabolic clearance of both the S enantiomer and the R enantiomer and potentiates warfarin anticoagulation. The anticoagulant effect is inhibited by drugs like barbiturates, rifampin, azathioprine, and carbamazepine, which increase hepatic clearance. Long-term alcohol consumption has a similar potential to increase the clearance of warfarin, but ingestion of even relatively large amounts of wine had little influence on the PT in normal volunteers who were given warfarin. The effect of enzyme induction on warfarin therapy has been discussed in more detail in a critical review.

Drugs also may influence the pharmacodynamics of warfarin by inhibiting the synthesis or of increasing the clearance of vitamin K-dependent coagulation factors or by interfering with other pathways of hemostasis. The anticoagulant effect of warfarin is augmented by second-generation and third-generation cephalosporins, which inhibit the cyclic interconversion of vitamin K, by thyroxine, which increases the metabolism of coagulation factors, and by clofibrate through an unknown mechanism. Doses of salicylates of > 1.5 g/day may augment the anticoagulant effect of warfarin. The commonly held view that acetaminophen does not significantly augment warfarin’s effect has been challenged. Thus, a potentiating effect of acetaminophen has been reported when large doses are used over prolonged periods. Although the potentiating effect may be minimal and inconsistent in some cases, large doses of acetaminophen have been shown to prolong the INR in a recent randomized, blinded trial. Acetaminophen’s mechanism of warfarin potentiation is possibly by inhibition of VKOR by a toxic metabolite of the drug, although the accumulation of this metabolite may vary among individuals, thus accounting for a variable potentiating effect. Heparin potentiates the anticoagulant effect of warfarin but in therapeutic doses produces only a slight prolongation of the PT. The mechanisms by which erythromycin and some anabolic steroids potentiate the anticoagulant effect of warfarin are unknown. Sulfonamides and several broad-spectrum antibiotic compounds may augment the anticoagulant effect of warfarin in patients consuming diets that are deficient in vitamin K by eliminating bacterial flora and aggravating vitamin K deficiency.

Aspirin, nonsteroidal antiinflammatory drugs (NSAIDs), penicillins in high doses, and moxalactam increase the risk of warfarin-associated bleeding by inhibiting platelet function. Of these drugs, aspirin is the most important because of its widespread use and prolonged effect. Aspirin and NSAIDs also can produce gastric erosions that increase the risk of upper GI bleeding. This effect can occur even with cyclooxygenase-2 inhibitors, which were originally believed to be less likely to predispose to gastric bleeding than NSAIDs. In one case-controlled analysis of 98,821 subjects on warfarin identified in linked databases, celecoxib and rofecoxib were associated with a 1.7-fold or 2.4-fold risk of GI hemorrhage, respectively. The risk of clinically important bleeding is heightened when high doses of aspirin are taken during high-intensity warfarin therapy (INR range, 3.0 to 4.5). However, low doses of aspirin (ie, 75 to 100 mg daily) combined with moderate-intensity and low-intensity warfarin anticoagulation therapy also are associated with increased rates of bleeding.

Nutritional supplements and herbal products are particularly problematic in that warfarin-treated patients often fail to inform physicians that they are using such products, and physicians rarely ask. In one survey of 1,200 subjects from four large anticoagulation clinics, one third used dietary supplements, and one third indicated that their provider failed to discuss potential interactions with them. There is
<table>
<thead>
<tr>
<th>Level of Causation</th>
<th>Antiinfectives</th>
<th>Cardiovascular</th>
<th>Analgesics, Antinflammatories, and Immunomodulators</th>
<th>CNS Drugs</th>
<th>GI Drugs and Food</th>
<th>Herbal Supplements</th>
<th>Other Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potentiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Highly probable</td>
<td>Ciprofloxacin</td>
<td>Amiodarone</td>
<td>Piroxicam</td>
<td>Acetaminophen</td>
<td>Clarithromycin</td>
<td>Miconazole Oral Gel</td>
<td>Potentiation</td>
</tr>
<tr>
<td></td>
<td>Cotrimoxazole</td>
<td>Clofibrate</td>
<td>Piroxicam</td>
<td>Diclofenac</td>
<td>Oxcarbazepine</td>
<td>Cimetidine</td>
<td>Fish oil</td>
</tr>
<tr>
<td></td>
<td>Erythromycin</td>
<td>Diltiazem</td>
<td>Piroxicam</td>
<td>Chronic</td>
<td>Miconazole Oral Gel</td>
<td>Boldo-funugreek</td>
<td>Mango</td>
</tr>
<tr>
<td></td>
<td>Fluconazole</td>
<td>Fenofibrate</td>
<td>Piroxicam</td>
<td>Ciprofloxacin</td>
<td>Miconazole Oral Gel</td>
<td>Quilinggao</td>
<td>Omeprazole</td>
</tr>
<tr>
<td></td>
<td>Isoniazid</td>
<td>Propafenone</td>
<td>Piroxicam</td>
<td>Ciprofloxacin</td>
<td>Miconazole Oral Gel</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metronidazole</td>
<td>Propranolol</td>
<td>Piroxicam</td>
<td>Ciprofloxacin</td>
<td>Miconazole Oral Gel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mixed</td>
<td>Miconazole Oral Gel</td>
<td>Sulfaphenazole</td>
<td>Piroxicam</td>
<td>Ciprofloxacin</td>
<td>Miconazole Oral Gel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mixed</td>
<td>Miconazole Vag Supp</td>
<td>Sulfaphenazole</td>
<td>(biphasic with later inhibition)</td>
<td>Ciprofloxacin</td>
<td>Miconazole Oral Gel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Probable</td>
<td>Anoxicillin/clavulanate</td>
<td>Aspirin</td>
<td>Acetaminophen</td>
<td>Diclofenac</td>
<td>Oxcarbazepine</td>
<td>F legionella</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Azithromycin</td>
<td>Fluvastatin</td>
<td>Acetaminophen</td>
<td>Diclofenac</td>
<td>Oxcarbazepine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clarithromycin</td>
<td>Quinidine</td>
<td>Acetaminophen</td>
<td>Diclofenac</td>
<td>Oxcarbazepine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Itraconazole</td>
<td>Ropinirole</td>
<td>Acetaminophen</td>
<td>Diclofenac</td>
<td>Oxcarbazepine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Levofloxacin</td>
<td>Simvastatin</td>
<td>Acetaminophen</td>
<td>Diclofenac</td>
<td>Oxcarbazepine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ritonavir</td>
<td>Tramadol</td>
<td>Acetaminophen</td>
<td>Diclofenac</td>
<td>Oxcarbazepine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td></td>
<td>Acetaminophen</td>
<td>Diclofenac</td>
<td>Oxcarbazepine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Possible</td>
<td>Anoxicillin</td>
<td>Amiodarone-induced toxicosis</td>
<td>Celecoxib</td>
<td>Indomethacin</td>
<td>Leflunomide</td>
<td>Plant extracts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anoxicillin/tranexamic rinse</td>
<td>Disopyramide</td>
<td>Celecoxib</td>
<td>Indomethacin</td>
<td>Leflunomide</td>
<td>Plant extracts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chloramphenicol</td>
<td>Gentiobiose</td>
<td>Celecoxib</td>
<td>Indomethacin</td>
<td>Leflunomide</td>
<td>Plant extracts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gatifloxacin</td>
<td>Metolazone</td>
<td>Celecoxib</td>
<td>Indomethacin</td>
<td>Etoposide</td>
<td>Plant extracts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Miconazole</td>
<td></td>
<td>Celecoxib</td>
<td>Indomethacin</td>
<td>Etoposide</td>
<td>Plant extracts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topical Gel</td>
<td></td>
<td>Celecoxib</td>
<td>Indomethacin</td>
<td>Etoposide</td>
<td>Plant extracts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NAHDLic Acid</td>
<td></td>
<td>Celecoxib</td>
<td>Indomethacin</td>
<td>Etoposide</td>
<td>Plant extracts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Norfloxacin Ofloxacine</td>
<td>NAHDLic Acid</td>
<td>Celecoxib</td>
<td>Indomethacin</td>
<td>Etoposide</td>
<td>Plant extracts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Saquinavir</td>
<td></td>
<td>Celecoxib</td>
<td>Indomethacin</td>
<td>Etoposide</td>
<td>Plant extracts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Terbinfine</td>
<td></td>
<td>Celecoxib</td>
<td>Indomethacin</td>
<td>Etoposide</td>
<td>Plant extracts</td>
<td></td>
</tr>
<tr>
<td>Highly improbable</td>
<td>Cefadroxil</td>
<td>Bezafibrate</td>
<td>Levamisole</td>
<td>Fluoxetine/diazepam</td>
<td>Quetiapine</td>
<td>Heparin</td>
<td>Levonorgestrel</td>
</tr>
<tr>
<td></td>
<td>Cefazolin</td>
<td>Bezafibrate</td>
<td>Levamisole</td>
<td>Fluoxetine/diazepam</td>
<td>Quetiapine</td>
<td>Heparin</td>
<td>Levonorgestrel</td>
</tr>
<tr>
<td></td>
<td>Sulbactam</td>
<td>Bezafibrate</td>
<td>Levamisole</td>
<td>Fluoxetine/diazepam</td>
<td>Quetiapine</td>
<td>Heparin</td>
<td>Levonorgestrel</td>
</tr>
<tr>
<td>Inhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Highly probable</td>
<td>Griseofulvin</td>
<td>Cholestyramine</td>
<td>Mesalamine</td>
<td>Barbiturates</td>
<td>Carbamazepine</td>
<td>High vitamin k content</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nafcillin Ribavirin</td>
<td>Rifampin</td>
<td>Cholestyramine</td>
<td>Mesalamine</td>
<td>Barbiturates</td>
<td>Carbamazepine</td>
<td>High vitamin k content</td>
</tr>
<tr>
<td></td>
<td>Rifampin</td>
<td>Bosentan</td>
<td>Azathioprine</td>
<td>Chloroquine</td>
<td>Salkylates</td>
<td>Sialic acid</td>
<td></td>
</tr>
<tr>
<td>Probable</td>
<td>Dicloxacillin</td>
<td>Telmisartan</td>
<td>Sulfasalazine</td>
<td>Chloroquine</td>
<td>Salkylates</td>
<td>Sialic acid</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ritonavir</td>
<td>Telmisartan</td>
<td>Sulfasalazine</td>
<td>Chloroquine</td>
<td>Salkylates</td>
<td>Sialic acid</td>
<td></td>
</tr>
<tr>
<td>Possible</td>
<td>Terbinfine</td>
<td>Telmisartan</td>
<td>Sulfasalazine</td>
<td>Chloroquine</td>
<td>Salkylates</td>
<td>Sialic acid</td>
<td></td>
</tr>
<tr>
<td>Highly improbable</td>
<td>Cloxacillin</td>
<td>Telmisartan</td>
<td>Sulfasalazine</td>
<td>Chloroquine</td>
<td>Salkylates</td>
<td>Sialic acid</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nafcillin/dicloxacillin</td>
<td>Telmisartan</td>
<td>Sulfasalazine</td>
<td>Chloroquine</td>
<td>Salkylates</td>
<td>Sialic acid</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ticloplatin</td>
<td>Furosemide</td>
<td>Propofol</td>
<td>Sialic acid</td>
<td>Salkylates</td>
<td>Sialic acid</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Propofol</td>
<td>Sialic acid</td>
<td>Salkylates</td>
<td>Sialic acid</td>
<td></td>
</tr>
</tbody>
</table>

*Data from Holbrook et al5 with permission.
also little or no standardization of the content of such products, especially herbal remedies, and reports of interactions often are anecdotal or single-case studies without good substantiation. Of the higher-quality studies, ginkgo and ginger were shown not to have an effect on warfarin in healthy subjects in a randomized, open-label, crossover study, and co-enzyme Q<sub>10</sub> (and ginkgo) were shown not to have an effect in a randomized, double-blind, crossover study. Ginseng was shown to reduce the effect of warfarin in a randomized, placebo-controlled trial. Not surprisingly, products with a high content of vitamin K, such as green tea, were shown to reduce the anticoagulant effect of warfarin.

Subjects receiving long-term warfarin therapy are sensitive to fluctuating levels of dietary vitamin K, which is derived predominantly from phylloquinones in plant material. Sadowski et al have listed the phylloquinone content of a wide range of foodstuffs, which also can be found on the Internet (http://ods.od.nih.gov/factsheets/cc/coumadin1.pdf). Phylloquinones act through the warfarin-insensitive pathway. Important fluctuations in vitamin K intake can occur in both healthy and sick subjects. An increased intake of dietary vitamin K that is sufficient to reduce the anticoagulant response to warfarin occurs in patients consuming green vegetables or vitamin K-containing supplements, while following weight-reduction diets, and in patients who have been treated with vitamin K supplements. Reduced dietary vitamin K intake potentiates the effect of warfarin in sick patients who have been treated with antibiotics and IV fluids without vitamin K supplementation and in patients who have states of fat malabsorption.

Hepatic dysfunction potentiates the response to warfarin through the impaired synthesis of coagulation factors. Hypermetabolic states produced by fever or hyperthyroidism increase warfarin responsiveness, probably by increasing the catabolism of vitamin K-dependent coagulation factors.

1.2 The Antithrombotic Effect of VKAs

The antithrombotic effect of VKAs has conventionally been attributed to their anticoagulant effect, which in turn is mediated by the reduction of four vitamin K-dependent coagulation factors. Evidence suggests, however, that the anticoagulant and antithrombotic effects can be dissociated and that the reduction of prothrombin and possibly factor X are more important than the reduction of factors VII and IX for the antithrombotic effect. This evidence is indirect and has been derived from the following observations. First, the experiments of Wessler and Gitel more than 40 years ago using a stasis model of thrombosis in rabbits showed that the antithrombotic effect of warfarin requires 6 days of treatment, whereas an anticoagulant effect develops in 2 days. The antithrombotic effect of warfarin requires the reduction of prothrombin (factor II), which has a relatively long half-life of about 60 to 72 h compared with 6 to 24 h for other vitamin K-dependent factors that are responsible for the more rapid anticoagulant effect. Second, in a rabbit model of tissue factor-induced intravascular coagulation, the protective effect of warfarin was mainly a result of lowering prothrombin levels. Third, Patel and associates demonstrated that clots formed from umbilical cord plasma containing about half the prothrombin concentration of plasma from adult control subjects generated significantly less fibrinopeptide A than clots formed from maternal plasma. The view that warfarin exerts its antithrombotic effect by reducing prothrombin levels is consistent with observations that clot-bound thrombin is an important mediator of clot growth and that reduction in prothrombin levels decreases the amount of thrombin generated and bound to fibrin, thereby reducing thrombogenicity.

The suggestion that the antithrombotic effect of warfarin is reflected in lower levels of prothrombin forms the basis for overlapping the administration of heparin with warfarin until the PT or INR is prolonged into the therapeutic range during the treatment of patients with thrombosis. Because the half-life of prothrombin is about 60 to 72 h, at least 4 days of overlap is necessary. Furthermore, the levels of native prothrombin antigen during warfarin therapy more closely reflect antithrombotic activity than the PT.

1.3 Monitoring Anticoagulation Intensity

The PT test is the most common test used to monitor VKA therapy. The PT responds to a reduction of three of the four vitamin K-dependent procoagulant clotting factors (ie, II, VII, X) that are reduced by warfarin at a rate proportional to their respective half-lives. Thus, during the first few days of warfarin therapy, the PT reflects mainly a reduction of factor VII, the half-life of which is approximately 6 h. Subsequently, the reduction of factors X and II contributes to prolongation of the PT. The PT assay is performed by adding calcium and thromboplastin to citrated plasma. Thromboplastins vary in responsiveness to a reduction of the vitamin K-dependent coagulation factors. An unresponsive thromboplastin produces less prolongation of the PT for a given reduction in vitamin K-dependent clotting factors than a responsive one. The responsiveness of a thromboplastin can be measured by assessing its international sensitivity index (ISI) [see below]. Highly sensitive thromboplastins (ISI, approx-
imately 1.0) that comprise human tissue factor produced by recombinant technology and defined phospholipid preparations are now available. Poller and Kirkwood have reviewed the history of standardization of the PT, and more detailed discussions can be found in prior editions of this article.

PT monitoring of warfarin treatment is not standardized when expressed in seconds, as a simple ratio of the patient’s plasma value to that of plasma from a healthy control subject, or as a percentage of diluted normal plasma. A calibration model, which was adopted in 1982, is now used to standardize reporting by converting the PT ratio measured with the local thromboplastin into an INR, calculated as follows:

$$\text{INR} = \frac{\text{patient PT/m}}{\text{mean normal PT}}^{\text{ISI}}$$

or

$$\log \text{INR} = \text{ISI} \times \log \frac{\text{patient PT}}{\text{mean normal PT}}$$

where ISI denotes the ISI of the thromboplastin used at the local laboratory to perform the PT measurement. The ISI reflects the responsiveness of a given thromboplastin to the reduction of the vitamin K-dependent coagulation factors compared with the primary World Health Organization (WHO) international reference preparations so that the more responsive the reagent, the lower the ISI value. AS the INR standard of reporting was widely adopted, a number of problems surfaced, which are listed in Table 3 and reviewed briefly below.

The INR is based on ISI values derived from the plasma of patients who had received stable anticoagulant doses for at least 6 weeks. As a result, the INR is less reliable early in the course of warfarin therapy, particularly when results are obtained from different laboratories. Even under these conditions, however, the INR is more reliable than the unconverted PT ratio and is thus recommended during both the initiation and maintenance of warfarin treatment. The validity of the INR in other conditions of impaired coagulation has not been fully evaluated. Although the INR may be no worse a measure of impaired coagulation in liver disease than the PT in raw seconds or the unconverted PT ratio, there is evidence that the PT reported in percent activity based on a dilution curve of normal plasma is a more accurate reflection of liver-induced coagulation impairment.

The INR accuracy can be influenced by reagents of different sensitivities and by the automated clot detectors now used in most laboratories. In general, the College of American Pathologists has recommended that laboratories use thromboplastin reagents that are at least moderately responsive (ie, ISI, < 1.7) and reagent/instrument combinations for which the ISI has been established and validated.

### Table 3—Potential Problems With the INR (Causes of Erroneous INR) [Section 1.3]*

<table>
<thead>
<tr>
<th>Problems</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incorrect PTR from erroneous PT determination due to pretest variables (sampling and blood collection problems)</td>
<td>Trisodium citrate concentration, storage time, storage temperature, evacuated tube effects, inadequate sample, variations in manual technique</td>
</tr>
<tr>
<td>Incorrect normal value</td>
<td>From nonuse of MNPT, error in MNPT due to: (1) unrepresentative selection; (2) technical faults (see above); (3) nonuse of geometric mean</td>
</tr>
<tr>
<td>Incorrect ISI of local thromboplastin reagent/test system from lack of reliability of the ISI result provided by the manufacturer</td>
<td>Incorrect choice of IRP; poor distribution of coumarin test samples across treatment range; inadequate numbers of test samples in ISI calibration; incorrect transformation of PTR of test plasmas to INR</td>
</tr>
</tbody>
</table>

*IRP = international reference preparation; MNPT = mean normal PT; PTR = prothrombin time ratio.

ISI values provided by the manufacturers of thromboplastin reagents are not invariably correct when applied locally, and this adversely affects the reliability of measurements. Local calibrations can be performed using plasma samples with certified PT values to determine the instrument-specific ISI. The mean normal plasma PT is not interchangeable with a laboratory control PT. Therefore, the use of other than a properly defined mean normal PT can yield erroneous INR calculations, particularly when less responsive reagents are used. The mean normal PT should be determined with each new batch of thromboplastin with the same instrument used to assay the PT.

The concentration of citrate that is used to anticoagulate plasma may affect the INR. In general, higher citrate concentrations (3.8%) lead to higher INR values and underfilling the blood collection tube spuriously prolongs the PT because...
excess citrate is present. Using collection tubes containing 3.2% concentrations of citrate for blood coagulation studies and adequately filling them can reduce this problem.

1.4 Optimal Therapeutic Range

The optimal target range for the INR is likely not to be the same for all indications. It is likely to be influenced not only by the indication for its use, but also by patient characteristics. Thus, in patients who are at very high risk of bleeding, it might be prudent to sacrifice some efficacy for safety. Bleeding, the major complication of oral anticoagulant therapy, is closely related to the intensity of anticoagulation.134–139 Accordingly, there has been interest in establishing the lowest effective therapeutic range.139–145 Universal agreement has not been reached on the optimal range for the various indications because data on the topic are incomplete. For example, European experts tend to recommend higher ranges for patients with mechanical heart valves than do North American experts.146,149–151

Investigators have used various methodologic approaches to establish the most appropriate range for different indications, as follows: (1) randomized trials in which patients are assigned to two different target ranges142–145,152,153; (2) indirect comparisons of results of randomized trials comparing patients treated with different intensities of anticoagulants or to those treated with another antithrombotic agent (usually aspirin)154–157; (3) subgroup analyses of observational studies (including within treatment groups of randomized trials) relating the observed INR or time spent in an INR range at the time of the outcome to either a bleeding event or a thromboembolic event137–140,158,159; and (4) case-control studies in which the INR levels at the time of an event are recorded and compared with INR levels in appropriately selected control subjects.141 All of these designs have limitations, but a randomized trial that compares two target INR ranges provides results that are closest to the truth because if appropriately designed, it minimizes bias.160

Four randomized studies142–145 have compared a moderate-intensity INR (approximately 2.0 to 3.0) to higher-intensity adjusted dose oral anticoagulation, and all reported that the moderate intensity reduced the risk of clinically important bleeding without reducing efficacy. In two of these studies, one in patients with venous thromboembolism142 and the other in patients with tissue heart valves,143 patients assigned to an INR intensity of 2.0 to 3.0 experienced less bleeding without apparent loss of efficacy than those who were assigned to an INR of 3.0 to 4.5. The results of these trials influenced the decision to lower the target INR range in North America to 2.0 to 3.0 for these and other indications.150,151 Recently, a randomized trial demonstrated that an INR of < 2.0 (INR target, 1.5 to 2.0)152 reduced the recurrence of venous thrombosis after an initial 3 to 6 months of standard treatment when compared to placebo. A subsequent clinical trial,153 however, found that maintaining an INR intensity of 2.0 to 3.0 in the same setting was more effective than a lower intensity of 1.5 to 2.0 and was not associated with a greater risk of bleeding.

Fixed minidose warfarin (1 mg daily) has been evaluated in a number of clinical settings. A small randomized trial161 reported the finding that fixed minidose warfarin (ie, 1 mg daily) was effective in preventing subclavian vein thrombosis in patients with malignancy who had indwelling catheters. Subsequently, two prospective cohort studies162,163 reported a reduced incidence of catheter thrombosis compared to historical controls in patients treated with 1 mg warfarin. In contrast, two larger randomized studies failed to support the effectiveness of warfarin.164,165 Heaton et al165 randomized 88 patients and objectively documented thrombosis in 18% of the warfarin group vs 12% of the placebo group. Couban et al164 randomized 255 patients and reported a 5% rate of symptomatic deep vein thrombosis (DVT) in the warfarin-treated group vs 4% in the placebo group. Investigators have reported similar findings of the ineffectiveness or reduced effectiveness of fixed minidose warfarin compared to dose-adjusted warfarin (INR, 2.0 to 3.0). Three of these studies164–170 evaluated its efficacy following major orthopedic surgery, and one each evaluated its efficacy in patients with indwelling catheters,164 atrial fibrillation,169 or acute myocardial infarction.170 Therefore, therapy with fixed minidose warfarin is either ineffective or much less effective than that with dose-adjusted warfarin in moderate-to-high-risk situations.

Oral anticoagulants are effective in preventing stroke171–175 and prolonging survival in patients with atrial fibrillation.176 Although moderate-intensity warfarin therapy (INR, 2.0 to 3.0) has not been directly compared with higher-intensity regimens in atrial fibrillation, the recommendation of a target INR of 2.0 to 3.0 is supported by the following evidence: (1) indirect comparison of several randomized trials155–157,177,178 showed that moderate-intensity warfarin regimen (INR, 2.0 to 3.0) resulted in a similar risk reduction as higher-intensity regimens; (2) a randomized trial179 reported that adjusted-dose warfarin therapy (INR, 2.0 to 3.0) was more effective than the combination of fixed-dose warfarin (3 mg) and aspirin; and (3) a subgroup analysis of one prospective study,140,159 the results of one case-control study,141 one prospective cohort study,180 and two prospective registries181,182
showed that the efficacy of oral anticoagulant agents is reduced when the INR falls to < 2.0.

In contrast to studies in the primary and secondary prevention of venous thrombosis and in the prevention of systemic embolism in patients with atrial fibrillation, warfarin at an INR of 2.0 to 3.0 has not been compared to a higher target INR in patients with acute myocardial infarction except when the oral anticoagulant was combined with aspirin. Two randomized trials183,184 reported that a higher-intensity warfarin regimen (INR, 3.0 to 4.0) is more effective than aspirin alone in preventing recurrent infarction, stroke, or death and is as effective and at least as safe as the combination of aspirin and a moderate-intensity anticoagulant regimen (INR, 2.0 to 2.5) following an episode of acute coronary syndrome. In contrast, the combination of aspirin and moderate-intensity anticoagulation (INR, 2.0 to 3.0) is more effective than aspirin alone following an episode of acute coronary syndrome, albeit, at a significantly greater risk of major bleeding.85 The combination of a lower-intensity anticoagulant regimen (INR, 1.5 to 2.5) and aspirin has been shown to be no more effective than aspirin alone.185,186 These secondary prevention studies contrast with those reported in the primary prevention of myocardial infarction in which low-intensity warfarin therapy (INR, 1.3 to 1.8) either used alone or in combination with aspirin was effective in high-risk men.88

In conclusion, a single therapeutic range for VKAs may not be optimal for all indications. However, a moderate-intensity INR (2.0 to 3.0) is effective for most indications. The possible exception is the primary prevention of myocardial infarction in high-risk patients in which a lower INR is preferable. In addition, a lower INR range (1.5 to 2.0) is effective in patients with venous thrombosis who have received 6 months of full-dose treatment (INR, 2.0 to 3.0), although the lower intensity is less effective than the higher intensity. Fixed-dose warfarin therapy has a reduced efficacy or none at all. The optimal intensity for patients with prosthetic heart valves remains uncertain, although there is evidence that such patients do not require the very-high-intensity regimens that have been used in the past. Although defining an appropriate range is an important step in improving patient outcomes, it is only the first of two steps. The second is ensuring that the targeted range is achieved promptly and maintained. In general, success in achieving this second goal has been suboptimal. It is better when the INR is controlled by experienced personnel in anticoagulant clinics and by using computer-assisted dosage adjustment.187 Clinicians can find specific recommendations regarding the optimal intensity of therapy for each of these indications in the articles in this supplement that deal with each indication.

2.0 Dose Management of VKA Therapy

Using the correct intensity of a coumarin anticoagulant and maintaining the patient in the therapeutic range are two important determinants of its therapeutic effectiveness and safety. High-quality dose management is needed to achieve and maintain the INR in the therapeutic range. The ability of the health-care provider to make appropriate dosage and follow-up decisions can have a major impact on therapeutic effectiveness. The comprehensive management of the VKAs requires a knowledgeable health-care provider, an organized system of follow-up, reliable PT monitoring, and good patient communication and education.187–189

The following discussion addresses a number of management issues pertaining to the use of VKAs. A systematic review of the literature was performed based on predefined criteria for the population at risk, the intervention or exposure evaluated, the outcomes assessed, and the methodology of the trials evaluated (Table 4).

2.1 Initiation and Maintenance Dosing

Following the administration of warfarin, an initial effect on the INR usually occurs within the first 2 or 3 days, depending on the dose administered, and an antithrombotic effect occurs within the next several days.190,191 Heparin or low-molecular-weight heparin should be administered concurrently when a rapid anticoagulant effect is required, and its administration should be overlapped with warfarin until the INR has been in the therapeutic range for at least 2 days to allow for further reduction of factors X and II. A loading dose (ie, > 10 mg) of warfarin is not recommended. A number of randomized studies have supported the use of a lower initiation dose. Harrison et al190 and Crowther et al192 found that in hospitalized, predominantly elderly patients, commencing with an average maintenance dose of 5 mg warfarin usually results in an INR of > 2.0 in 4 or 5 days with less excessive anticoagulation compared to that with an initial 10-mg dose. Kovacs et al,193 however, found that in outpatients who had been treated for venous thromboembolism, an initial 10-mg dose for the first 2 days of therapy compared to a 5-mg dose resulted in a more rapid achievement of a therapeutic INR (1.4 days earlier) without a difference in rates of excessive anticoagulation. This study,193 however, included fewer patients over 75 years of age than did the study of hospitalized patients.192 Thus, there is room for flexibility in selecting a starting dose of warfarin. Some clinicians prefer to use a large starting dose (eg, 7.5 to 10 mg), whereas a starting dose of ≤ 5 mg might be appropriate in elderly patients; in patients with impaired nutrition, liver dis-
ease, or congestive heart failure (CHF); and in patients who are at high risk of bleeding. An initial dose of 2 to 3 mg is appropriate for patients who have undergone heart valve replacement.\textsuperscript{194,195}

In the past few years, studies have shown that pharmacogenetics plays an important role in the pharmacokinetic and pharmacodynamic behavior of warfarin. Single nucleotide polymorphisms (SNPs) in the gene coding for CYP2C9, the principal enzyme responsible for metabolizing the S enantiomer of warfarin, will significantly alter the rate of metabolism (i.e., half-life) of warfarin, affecting both the rapidity of initial effect and the dose required to maintain a therapeutic INR. Similarly, various mutations in the gene coding for the VKORC1 enzyme will lead to a protein that is either sensitive or resistant to warfarin inhibition and, thus, affect the initial dose required to achieve a therapeutic INR as well as the dose required to maintain a therapeutic INR. In a retrospective, observational analysis, Joffe et al\textsuperscript{196} found that CYP2C9 polymorphisms independently predicted low warfarin requirements after adjusting for body mass index, age, acetaminophen use, and race (odds ratio [OR], 24.8; 95% confidence interval [CI], 3.83 to 160.78). Gage et al\textsuperscript{197} developed a dosing algorithm based on CYP2C9 polymorphisms along with clinical and demographic factors in 369 patients on stable warfarin therapy. Older age, low body surface area, and the presence of CYP2C9*2 or CYP2C9*3 alleles were strongly associated with lower warfarin dose requirements ($p < 0.001$). The maintenance dose decreased by 8% per decade of age, by 13% per SD in body surface area, by 19% per CYP2C9*2 allele, and by 30% per CYP2C9*3 allele. These factors, along with gender, accounted for 39% of the variance.
in the maintenance dose of warfarin. Sconce et al\textsuperscript{49} similarly found that age, height, and CYP2C9 genotype significantly contributed to S-warfarin clearance in 297 patients on stable anticoagulation. The mean daily warfarin dose was highest in those who were homozygous for the CYP2C9 wild type compared to the CYP2C9*2 and CYP2C9*3 alleles. The impact of these mutations in CYP2C9 also affects acenocoumarol, although to a lesser degree because the anticoagulation potencies of the R and S enantiomers are comparable.\textsuperscript{198}

Genetic mutations in the gene coding for the VKORC1 often involve several mutations, leading to various haplotypes that cause greater resistance to warfarin therapy. Harrington et al\textsuperscript{150} found a warfarin-resistant individual who had high serum warfarin concentrations and a 196G > A transition, predicting a Val66Met substitution in VKORC1. In a study of 147 patients, D’Andrea et al\textsuperscript{46} found that patients with a 1173CC genotype required a higher mean maintenance dose than those with a CT or TT genotype, as did Quetein et al.\textsuperscript{199} who found that a 1173 C > T polymorphism was significantly associated with the risk of anticoagulation overdose. By identifying a number of noncoding SNPs, Rieder et al\textsuperscript{47} were able to infer that five major haplotypes are associated with different dose requirements for maintaining a therapeutic INR. The maintenance dose ranged from a low of 2.7 mg warfarin per day for the sensitive haplotypes up to 6.2 mg per day for the resistant haplotypes. Asian Americans had the higher proportion of sensitive haplotypes, whereas African Americans more frequently exhibited the resistant haplotypes (Table 1). Sconce et al\textsuperscript{49} found that a combination of CYP2C9 and VKORC1 genotypes plus height produced the best predictive model for estimating warfarin dose, whereas Vecsler et al\textsuperscript{200} reported that CYP2C9 and VKORC1 genotypes together with age, gender, race, and use of simvastatin or amiodarone may predict initial and maintenance warfarin dosing requirements, but also because certain genotypes have been associated with adverse events.

These findings are significant not only because they may predict initial and maintenance warfarin dosing requirements, but also because certain genotypes have been associated with adverse events. Thus, Higashi et al\textsuperscript{38} studied 185 patients, 58 with at least one variant genotype of CYP2C9, and found in those with variant genotypes an increased risk of having INRs above range (hazard ratio [HR], 1.40; 95% CI, 1.03 to 1.90) and a significant risk of a serious or life-threatening bleeding event (HR, 2.39; 95% CI 1.18 to 4.86). The latter hazard estimate was based on a few events in a very small number of patients with the variant genotypes. Joffe et al\textsuperscript{196} also studying CYP2C9 SNPs, found an upward trend in rates of an INR > 6.0 or of bleeding in patients who were categorized as heterozygotes or compound hetero/homozygotes compared to wild types, as did Veenstra et al\textsuperscript{34} A similar increased risk of bleeding was seen in patients with these polymorphisms who were taking acenocoumarol but not phenprocoumon.\textsuperscript{41}

The ability to determine mutations in the genes coding for these two proteins will likely influence future dosing patterns (\textit{eg}, algorithms), but just how much value they will add to conscientious monitoring of the INR and dose management remains to be determined.\textsuperscript{201} To date, only pilot trials of genetic-based dosing have been performed with mixed results. Hillman et al\textsuperscript{202} randomized 38 patients to standard vs genetic-based dosing and showed a nonstatistical decrease in adverse events (6 of 20 in the standard group vs 2 of 18 in the genetic-based dosing group). All patients were dosed based on an algorithm taking into account mutations in CYP2C9. Voora et al\textsuperscript{203} dosed a single cohort of 48 orthopedic patients according to their CYP2C9 genotype in addition to age, weight, height, gender, race, and use of simvastatin or amiodarone. Although patients with a CYP2C9 variant promptly achieved a stable dose, they continued to be at higher risk of an INR > 4.0 than patients with a normal genotype. The use of genetic testing before initiating warfarin therapy is impractical in most centers because it is not available in a timely manner. The future role of genetic testing in assisting dose prediction only can be determined by appropriately designed randomized trials.

After 4 to 5 days of concomitant warfarin and heparin therapy, heparin is discontinued when the INR has been in the therapeutic range on two measurements approximately 24 h apart. This delay in discontinuing heparin allows factors X and II to be reduced to their plateau levels. If treatment initiation is not urgent (\textit{eg}, in chronic stable atrial fibrillation), warfarin administration, without concurrent heparin administration, can be commenced out of hospital with an anticipated maintenance dose of 4 to 5 mg/d. In patients with a known protein C deficiency or another thrombophilic state, it would be prudent to begin heparin therapy before or at the same time as starting warfarin therapy to protect against a possible early hypercoagulable state caused by a warfarin-mediated reduction in the vitamin K-dependent coagulation inhibitors.\textsuperscript{204}

Because dose requirements often change during maintenance therapy, physicians use various strategies to ensure that dosing instructions are simple and clear for the patient. Some providers prefer to use a fixed tablet strength of warfarin and to use alternate dose amounts (tablets or fraction of tablets) per day. Others prefer a uniform daily amount that might require the patient to have different tablet strengths. Both methods achieve similar outcomes, although the former practice may be more confusing for the patient.\textsuperscript{205,206}
Recommendation

2.1.1. In patients beginning VKA therapy, we recommend the initiation of oral anticoagulation, with doses between 5 and 10 mg for the first 1 or 2 days for most individuals and subsequent dosing based on the INR response (Grade 1B). At the present time, for patients beginning VKA therapy, without evidence from randomized trials, we suggest against the use of pharmacogenetic-based initial dosing to individualize warfarin dosing (Grade 2C).

2.2 Initiation of Anticoagulation in the Elderly

The dose required to maintain a therapeutic range for patients over 60 years of age decreases with increasing age, possibly because of a reduction in the clearance of warfarin with age. Gender also influences dose, with women requiring less warfarin to maintain a therapeutic INR than men at an equivalent age. In a prospective cohort study of elderly patients who were given three initial doses of 4 mg, Siguret et al were able to accurately predict the maintenance dose based on the INR on the third day in 73% of patients, and within 1 mg of the maintenance dose in 95% of patients; no patient had an INR > 4.0. Therefore, in elderly patients, the initial dose of warfarin should not be > 5 mg and in some cases (ie, in patients with a high risk of bleeding; in those who are undernourished, have congestive heart failure (CHF), or have liver disease; or in those who have undergone heart valve replacement surgery), it should be less. Other factors that may influence the response to anticoagulation in elderly patients include the potential for a greater number of other medical conditions and/or concurrent drug use. Consequently, it is advisable to monitor older patients more frequently in order to maximize their time in the therapeutic range (TTR).

Recommendation

2.2.1. In elderly patients or in patients who are debilitated, malnourished, have CHF, have liver disease, have had recent major surgery, or are taking medications known to increase the sensitivity to warfarin (eg, amiodarone), we recommend the use of a starting dose of ≤ 5 mg (Grade 1C) with subsequent dosing based on the INR response.

2.3 Frequency of Monitoring

In hospitalized patients, PT monitoring is usually performed daily, starting after the second or third dose until the TTR has been achieved and maintained for at least 2 consecutive days; then two or three times weekly for 1 to 2 weeks; then less often, depending on the stability of INR results. In outpatients starting warfarin therapy, initial monitoring may be reduced to every few days until a stable dose response has been achieved. When the INR response is stable, the frequency of testing can be reduced to intervals as long as every 4 weeks, although evidence suggests that testing more frequently than every 4 weeks will lead to greater TTR. If adjustments to the dose are required, then the cycle of more frequent monitoring should be repeated until a stable dose response can again be achieved.

The optimal frequency of long-term INR monitoring is influenced by patient compliance, transient fluctuations in the severity of comorbid conditions, the addition or discontinuation of other medications, changes in diet, the quality of dose-adjustment decisions, and whether the patient has demonstrated a stable dose response. Some investigators have attempted to develop predictive models with the goal of reducing the frequency of testing without sacrificing quality. Pengo et al randomized 124 patients with prosthetic mechanical heart valves who were on stable therapy for at least 6 months to INR monitoring either at 6-week or at 4-week intervals. They found no difference in time in, above, or below range between the groups; however, the actual interval of monitoring was 24.9 days in the 6-week group and 22.5 days in the 4-week group (p < 0.0003). Other clinical trials have suggested that during long-term treatment, the TTR and, presumably, fewer adverse events can be maximized by more frequent testing. This finding is particularly true in studies using patient self-testing (PST) in which access to testing is virtually unlimited. Horstkotte et al addressed this issue in 200 patients with mechanical cardiac valves and found that the percentage of INRs within the target range increased from 48% when monitoring was performed at an average interval of 24 days to 89% when monitoring was performed at an average of every 4 days by home PST using a point-of-care (POC) monitor. In a recent study of > 4,000 patients with chronic atrial fibrillation and > 250,000 INRs, Shalev et al found a greater time in range as the testing interval decreased from every 5 weeks to every 3 weeks (41 to 48%, p < 0.0005), and the investigators suggested that patients should be monitored no longer than every 4 weeks. More frequent monitoring may be advisable for patients who exhibit an unstable dose response.

Recommendations

2.3.1. In patients beginning VKA therapy, we suggest that INR monitoring be started after...
the initial two or three doses of oral anticoagulation therapy (Grade 2C).

2.3.2. For patients who are receiving a stable dose of oral anticoagulants, we suggest monitoring at an interval of no longer than every 4 weeks (Grade 2C).

2.4 Management of Nontherapeutic INRs With or Without Bleeding

Fluctuations in INR may occur because of any one or more of the following conditions: (1) inaccuracy in INR testing; (2) changes in vitamin K intake; (3) changes in vitamin K or warfarin absorption; (4) changes in warfarin metabolism; (5) changes in vitamin K-dependent coagulation factor synthesis or metabolism; (6) other effects of concomitant drug use; or (7) patient noncompliance. The management of patients whose INR is outside the therapeutic range is controversial because many of the various options have not been compared.

When the INR is nontherapeutic, there are many options for dose adjustments. Patients whose INR is just outside the therapeutic range can be managed by either adjusting the dose up or down in increments of 5 to 20% based on the cumulative weekly dose of warfarin or by more frequent monitoring, the latter with the expectation that the INR will return to therapeutic levels without a dosage change. Because the absolute daily risk of bleeding is low even when the INR is excessively prolonged, many physicians manage patients with minimally elevated INRs by more frequent monitoring without a dose change,

Hylek et al.

reported that when two doses of warfarin were withheld in patients whose INR was > 6.0, the INR returned more slowly if their maintenance dose was lower, they were of older age, they had a higher initial INR, they had decompensated CHF, or they had active cancer. Among 562 patients with an INR between 6.0 and 10.0, the subsequent INR measurement after withholding two doses of warfarin was < 4.0 in 67% of patients and < 2.0 in 12% of patients. Garcia et al.

assessed the management of 979 patients who presented with an INR between 5.0 and 9.0. Vitamin K was used in only 8.7% of the episodes of elevated INR values, and major bleeding occurred in 1% of all patients in the following 30 days. If the patient is at intrinsically high risk of bleeding or if bleeding has already developed, patients also can be managed by omitting one or more doses, by more frequent monitoring, and by actively intervening to lower the INR more rapidly.

The interventions include administering vitamin K and/or infusing fresh frozen plasma,

prothrombin concentrations,

or recombinant factor VIIa.

The choice of approach is based largely on the potential risk of bleeding, the presence of active bleeding, and the level of the INR. Crowther et al.

compared either stopping warfarin or administering oral vitamin K in a randomized trial of patients with an INR of between 4.5 and 10. Those not treated with vitamin K experienced a higher rate of minor bleeding in the following 3 months compared to those who were treated with vitamin K (4% vs 17%, respectively; p = 0.05). Ageno et al.

randomized 59 mechanical heart valve patients with an INR between 6.0 and 12.0 to either 1 mg of oral vitamin K or to no treatment. Although no major bleeding occurred in either group in this small study, 1 mg of oral vitamin K more commonly returned a prolonged INR value to the therapeutic or near-therapeutic range within 1 day than in the no-treatment group (mean INR in 24 h, 2.99 vs 5.23, respectively). Three patients in the vitamin K group had an INR of < 1.8 compared to zero in the control group. Finally, Gunther et al.

managed 75 episodes of an INR > 10, treating 51 episodes with low-dose vitamin K (2 mg) compared with 24 episodes with no treatment. There were no major bleeds in the treated patients vs three clinically important bleeds in the nontreated patients.

The response to vitamin K administered subcutaneously is less predictable than to oral vitamin K and is sometimes delayed.

Some studies have confirmed earlier reports that oral administration is predictably effective and has the advantages of safety and convenience over parenteral routes. If a decision is made to use vitamin K, it should be administered in a dose that will quickly lower the INR into a safe, but not subtherapeutic range without causing resistance once warfarin is reinstated or without exposing the patient to the risk of anaphylaxis. High doses of vitamin K, though effective, may lower the INR more than is necessary and may lead to warfarin resistance for 1 week or more. Low doses of vitamin K and slow infusion rates are recommended, but there is no definitive evidence that anaphylaxis can be avoided by using low doses or slow infusion rates.

A dose range of 1.0 to 2.5 mg is effective when the INR is between 5.0 and 9.0, but larger doses (ie, 2.5 to 5 mg) are required to correct INRs of > 9.0. Vitamin K also can be administered by slow IV infusion when there is a greater urgency to reverse anticoagulation or an impairment in vitamin K absorption. IV injection may be associated with anaphylactic reactions, although such reactions have occurred with non-IV routes of administration.

For life-threatening bleeding, immediate correction of the INR is mandatory. Although fresh frozen plasma can be given in this situation, immediate and
full correction can only be achieved by the use of factor concentrates because the amount of fresh frozen plasma required to fully correct the INR is considerable and may take hours to infuse. Yasaka et al found that a dose of 500 IU of PCC was optimal for rapid reversal for an INR of < 5.0 but that higher doses might be needed for more elevated INRs. Although not currently approved for this indication, recombinant factor VIIa has been shown to be effective in reversing therapeutic INRs to normal at varying doses (10 μg/kg) to maximum cumulative dose of 400 μg/kg) in healthy volunteers and to reversing supratherapeutic INRs and/or bleeding in patients on warfarin, again at varying doses (15 to 90 μg/kg). In a prospective observational study of 16 patients with major bleeding on warfarin, Dager et al found that a dose of approximately 16 μg/kg was adequate for rapid reversal of the INR and to achieve a desirable hemostatic effect in 14 patients. Recombinant factor VIIa has a short half-life, and vitamin K should be administered simultaneously to stimulate factor production. Recombinant factor VIIa also has been associated with an increased risk of thromboembolic events as have some PCCs. Thus, one must take this potential adverse effect into consideration when using such agents. Finally, the use of PCCs or recombinant factor VIIa may vary depending on the availability of such products in one’s institution.

Table 5—Recommendations for Managing Elevated INRs or Bleeding in Patients Receiving VKAs (Section 2.4)*

<table>
<thead>
<tr>
<th>Condition†</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>INR more than therapeutic range but &lt; 5.0; no significant bleeding</td>
<td>Lower dose or omit dose; monitor more frequently and resume at lower dose when INR therapeutic; if only minimally above therapeutic range, no dose reduction may be required (Grade 1C).</td>
</tr>
<tr>
<td>INR ≥ 5.0, but &lt; 9.0; no significant bleeding</td>
<td>Omit next one or two doses, monitor more frequently, and resume at an appropriately adjusted dose when INR in therapeutic range. Alternatively, omit dose and give vitamin K (1–2.5 mg po), particularly if at increased risk of bleeding (Grade 1C). If more rapid reversal is required because the patient requires urgent surgery, vitamin K (≥ 5 mg po) can be given with the expectation that a reduction of the INR will occur in 24 h. If the INR is still high, additional vitamin K (1–2 mg po) can be given (Grade 2C).</td>
</tr>
<tr>
<td>INR ≥ 9.0; no significant bleeding</td>
<td>Hold warfarin therapy and give higher dose of vitamin K (2.5–5 mg po) with the expectation that the INR will be reduced substantially in 24–48 h (Grade 1B). Monitor more frequently and use additional vitamin K if necessary. Resume therapy at an appropriately adjusted dose when INR is therapeutic.</td>
</tr>
<tr>
<td>Serious bleeding at any elevation of INR</td>
<td>Hold warfarin therapy and give vitamin K (10 mg by slow IV infusion), supplemented with FFP, PCC, or rVIIa, depending on the urgency of the situation; vitamin K can be repeated q12h (Grade 1C).</td>
</tr>
<tr>
<td>Life-threatening bleeding</td>
<td>Hold warfarin therapy and give FFP, PCC, or rVIIa supplemented with vitamin K (10 mg by slow IV infusion). Repeat, if necessary, depending on INR (Grade 1C).</td>
</tr>
<tr>
<td>Administration of vitamin K</td>
<td>In patients with mild to moderately elevated INRs without major bleeding, give vitamin K orally rather than subcutaneously (Grade 1A).</td>
</tr>
</tbody>
</table>

*See Table 4 for other abbreviations.†If continuing warfarin therapy is indicated after high doses of vitamin K, then heparin or low-molecular-weight heparin can be given until the effects of vitamin K have been reversed, and the patient becomes responsive to warfarin therapy. It should be noted that INR values > 4.5 are less reliable than values in or near the therapeutic range. Thus, these guidelines represent an approximate guide for high INRs.

For patients with subtherapeutic INRs during long-term therapy, no specific studies have examined the optimal method of correction. Because the average daily risk of thrombosis for most indications is quite small, except in exceptional circumstances, most patients do not need to be covered with a rapidly acting anticoagulant, such as heparin or low-molecular-weight heparin. Rather, the weekly cumulative dose of warfarin is usually increased by 10 to 20%, and more frequent monitoring is instituted until the INR is stable. In some cases, patients may be given a one-time larger dose followed by more frequent monitoring with or without a change in the cumulative weekly dose.

Recommendations

2.4.1. For patients with INRs above the therapeutic range but < 5.0 and with no significant bleeding, we recommend lowering the dose or omitting a dose, monitoring more frequently, and resuming therapy at an appropriately adjusted dose when the INR is at a therapeutic level. If only minimally above therapeutic range or associated with a transient causative factor, no dose reduction may be required (all Grade 1C).

2.4.2. For patients with INRs ≥ 5.0 but < 9.0 and no significant bleeding, we recommend omitting the next one or two doses, monitoring more frequently, and resuming therapy at an appropriately adjusted dose when the INR is at a therapeutic level (Grade 1C). Alternatively, we suggest omitting a dose and administering vita-
min K (1 to 2.5 mg) orally, particularly if the patient is at increased risk of bleeding (Grade 2A). If more rapid reversal is required because the patient requires urgent surgery, we suggest vitamin K (≤5 mg) orally with the expectation that a reduction of the INR will occur in 24 h. If the INR is still high, we suggest additional vitamin K (1 to 2 mg) orally (Grade 2C).  

2.4.3. For patients with INRs ≥9.0 and no significant bleeding, we recommend holding warfarin therapy and administering a higher dose of vitamin K (2.5 to 5 mg) orally, with the expectation that the INR will be reduced substantially in 24 to 48 h (Grade 1B). Clinicians should monitor the INR more frequently, administer additional vitamin K if necessary, and resume therapy at an appropriately adjusted dose when the INR reaches the therapeutic range.

2.4.4. In patients with serious bleeding and elevated INR, regardless of the magnitude of the elevation, we recommend holding warfarin therapy and giving vitamin K (10 mg) by slow IV infusion supplemented with fresh frozen plasma, PCC, or recombinant factor VIIa, depending on the urgency of the situation. We recommend repeating vitamin K administration every 12 h for persistent INR elevation (all Grade 1C).  

2.4.5. In patients with life-threatening bleeding (e.g., intracranial hemorrhage) and elevated INR, regardless of the magnitude of the elevation, we recommend holding warfarin therapy and administering fresh frozen plasma, PCC, or recombinant factor VIIa supplemented with vitamin K (10 mg) by slow IV infusion, repeated, if necessary, depending on the INR (Grade 1C).

2.4.6. In patients with mild to moderately elevated INRs without major bleeding, we recommend that when vitamin K is to be given, it be administered orally rather than subcutaneously (Grade 1A).

2.5 Management of Variable INRs

Although it has long been known that changes in dietary vitamin K intake may influence the stability of the INR in patients on warfarin, only recently have trials been conducted to assess the impact that vitamin K can have on therapeutic stability. In 1993, Sorano et al250 showed that by stabilizing the intake of dietary vitamin K, more stable anticoagulation can be achieved. By comparing the daily vitamin K intake in 26 unstable patients with 26 stable control patients, Sconce et al251 showed that the unstable patients had poorer intake of vitamin K. Kurnik et al252 showed that in vitamin K-depleted patients, very small amounts of vitamin K-containing vitamins will influence the INR to a greater extent than in those with an adequate vitamin K status. In a study of 12 healthy volunteers on oral anticoagulation, Schurgers et al253 found that a daily dose of vitamin K of at least 150 μg was needed to alter the INR response. Reese et al254 used a retrospective analysis to assess the effect of a daily dose of 100 μg of vitamin K1 in nine unstable patients. These patients experienced an increase in percent INRs (range, 32 to 57%) in response to the daily vitamin K. In a prospective, open-label, crossover study, Ford et al255 found that five of nine patients improved their stability with low-dose administration of vitamin K. As expected, the INR initially decreased in patients given vitamin K, and an increased dose of warfarin was needed to reestablish an INR in the therapeutic range, which took 2 to 35 days to achieve. Thus, patients must be monitored carefully if this intervention is tried. Finally, Sconce et al256 conducted the first randomized, blinded trial in 70 unstable patients over a 6-month period. Vitamin K supplementation resulted in a significantly greater decrease in SD of the INR than with placebo (−0.02 ± 0.14 vs −0.11 ± 0.18; p < 0.001) and a significantly greater increase in percentage of time within target INR range (28% ± 20% vs 15 ± 20%; p < 0.01). In these last two studies, variable INR was defined as requiring a minimum of three warfarin dose changes or three INRs outside of the therapeutic range in the preceding 6 months257 or an INR SD > 0.5 with at least three warfarin dose changes during the previous 6 months.258 In determining whether a patient with a variable INR response is suitable for supplemental vitamin K, one must be certain to exclude the known multiple causes of INR variability, and this requirement was also part of the two definitions above.

Recommendation

2.5.1. For patients receiving long-term warfarin therapy with a variable INR response not attributable to any of the usual known causes for instability, we suggest a trial of daily low-dose oral vitamin K (100 to 200 μg), with close monitoring of the INR and warfarin dose adjustment to counter an initial lowering of the INR in response to vitamin K (Grade 2B).

2.6 Management of Oral Anticoagulation During Invasive Procedures

Clinicians often are required to decide how to manage patients who are receiving long-term anticoagulant therapy and require an invasive procedure.257,258 Because of the complexity of this decision, the “Peri-
operative Management” chapter in this supplement is devoted to this topic (in conjunction with managing antiplatelet therapy during invasive procedures), assessing the literature and arriving at consensus recommendations.

2.7 Management of INRs in the Antiphospholipid Syndrome

Patients who have a lupus anticoagulant or anticardiolipin/β-2-glycoprotein 1 antibodies have an increased risk of thrombosis. Evidence from older observational studies suggested that clinical outcomes are improved when the therapeutic range for such patients treated with warfarin was closer to 2.5 to 3.5 rather than 2.0 to 3.0. One potential explanation for the requirement of a higher INR is based on the observation that lupus anticoagulants are able to prolong the INR. Although lupus anticoagulants typically cause prolongation of the activated partial thromboplastin time, they also may cause mild prolongation of the INR or, in the presence of specific antibodies to prothrombin, more marked prolongation of the INR. The degree of prolongation of the INR induced by lupus anticoagulants appears to depend on the reagent used. One study found that simultaneous INR values from the same sample of blood from patients who have a lupus anticoagulant and were receiving oral anticoagulants differed from 0.4 to 6.5 between reagents. Two studies demonstrated that the standardization of INR values using either calibrated reference plasmas or locally assigned analyzer-specific ISI values can significantly reduce this variability. These latter techniques appear to enable oral anticoagulants to be reliably monitored using the INR system for some reagents but not all. Other techniques for monitoring oral anticoagulant therapy for patients with lupus anticoagulants include the measurement of prothrombin activity and native prothrombin concentration and the prothrombin and proconvertin test. The validity and reliability of these latter tests have not been rigorously evaluated in controlled clinical trials for patients with lupus anticoagulants.

In a randomized controlled trial of 114 patients with antiphospholipid syndrome who had been treated with warfarin, Crowther et al. assigned patients to an INR of either 3.1 to 4.0 or 2.0 to 3.0. They found no difference in recurrent thromboembolism between the two groups (10.7% vs 3.4%; HR, 3.1; 95% CI, 0.6 to 15.0 high intensity vs conventional treatment), although 75% of all patients who had a recurrence were at subtherapeutic levels (INR < 2.0) or not receiving warfarin. The high-intensity group had significantly more men and a trend toward more patients with underlying lupus or arterial disease. There was no difference in major bleeding. In a similar study, Finazzi et al. randomized 109 patients with antiphospholipid syndrome to an INR of 3.0 to 4.5 vs conventional treatment (INR range, 2.0 to 3.0) with median follow-up of 3.6 years. Recurrent thrombosis occurred in 11.5% in the high-intensity group vs 5.5% in the conventional group (HR, 1.97%; 95% CI, 0.49 to 7.89). There was no significant difference in major bleeding (27.8% vs 14.6%; HR, 2.18; 95% CI, 0.92 to 5.15). Other investigators have reported similar outcomes in an 8-year follow-up study and in a retrospective cohort study.

Recommendation

2.7.1. In patients who have a lupus inhibitor and who have no additional risk factors and no lack of response to therapy, we recommend a therapeutic target INR of 2.5 (INR range, 2.0 to 3.0) (Grade 1A). In patients who have recurrent thromboembolic events with a therapeutic INR, we suggest a target INR of 3.0 (INR range, 2.5 to 3.5) [Grade 2C].

3.0 Adverse Events and Their Management

3.1 Definition of Major and Minor Hemorrhage

Precise estimates of hemorrhagic event rates are complicated by the inconsistency among classification schemes in clinical research studies. Fihn et al. proposed the following three categories of bleeding: (1) minor (reported, but not requiring additional testing, referrals, or visits); (2) major (requiring treatment, medical evaluation, or at least 2 U blood); and (3) life threatening (leading to cardiac arrest, surgical/angiographic intervention, or irreversible sequela). Most other investigators, however, divide adverse events into minor and major categories, with major events including fatal or life-threatening bleeds (eg, intracranial or retroperitoneal) or bleeding with a defined drop in hemoglobin, leading to transfusion of a specified number of units of blood and/or hospitalization. The reader should be aware of these differences when interpreting the results from clinical studies. The reader is referred to the “Hemorrhage Complications” chapter in this supplement for an indepth discussion of hemorrhagic adverse events with anticoagulant therapy.

3.2 Factors Predictive of Adverse Events

3.2.1 Intensity of Treatment

The most important factor influencing the risk of bleeding is the intensity of anticoagulant therapy. The relationship between bleed-
ing and the level of INR has been reported to rise steeply as the INR increases > 5.0.\textsuperscript{138,139,274,276} The optimal target range for each indication and the lowest effective range are discussed specifically in other articles in this supplement pertaining to each indication.

3.2.2 TTR

The relationship between the intensity of treatment and the risk of an adverse event has been evaluated by examining the frequency of an event as a function of the TTR.\textsuperscript{189,277,278} A strong relationship between TTR and bleeding or thromboembolic rates has been observed across a large number of studies,\textsuperscript{138,171–173,189,274,276–281} with different patient populations, different target ranges, different scales for measuring intensity of anticoagulation (ie, PT, PT ratio, and INR), different methods of measuring TTR, and different models of dose management. In a large, retrospective analysis of patients with mechanical heart valves, Cannegieter et al\textsuperscript{138} reported a strong relationship between TTR and major bleeds or thromboembolism for INRs above or below the therapeutic range. A similar relationship has been demonstrated for other groups of patients.\textsuperscript{141,274} The percentage of INRs or TTR highly depends on the quality of dose management as reflected in studies that report TTR. Poor quality of dose management results in a high rate of low INRs during the first 3 months of treatment following an acute DVT, which in turn, predicts for a higher rate of subsequent recurrence.\textsuperscript{189,282} The quality of dose management is reflected by studies where dose management is provided in a usual care (UC) setting, by an anticoagulation management service (AMS), by PST or patient self-management (PSM), or in the setting of a randomized trial. Table \textsuperscript{6}\textsuperscript{172–175,283–308} summarizes data from a range of studies reporting TTR, with results grouped according to the model of dose management. Historically, many studies have failed to measure or report the quality of anticoagulation management as reflected by TTR.\textsuperscript{309} We believe that this is a deficiency that can lead to the erroneous interpretation of results, and we urge investigators to measure and report TTR in their studies.

TTR can be determined by a variety of methods, and, therefore, comparisons between studies may be difficult.\textsuperscript{310} TTR is most commonly expressed by one of three methods: (1) as the fraction of INR values that are within therapeutic range (eg, the number of INRs in range divided by the total number of INR tests); (2) as the “cross-section of the files” methodology, which assesses the fraction of patients (ie, INRs) in range at one point in time compared to the total number of patients who had an INR at that point in time; or (3) the linear interpolation method of Rosendaal et al,\textsuperscript{311} which assumes that a linear relationship exists between two INR values and allocates a specific INR value to each day between tests for each patient. Each approach has its advantages and disadvantages.\textsuperscript{310} Furthermore, the results of all of these methods depend on whether an exact or an expanded therapeutic range is used,\textsuperscript{312} whether warfarin-naïve patients (those just beginning therapy) are included or only patients already on established therapy,\textsuperscript{313,314} whether INRs obtained during invasive procedures when warfarin therapy might be interrupted are included, and whether different oral anticoagulant preparations (eg, warfarin, phenprocoumon, or acenocoumarol) are included.\textsuperscript{314–316} Because clinical outcome studies comparing one methodology over another and their correlation with adverse events have not been done, no one method can be recommended, and the reader should be aware of these differences.

3.2.3 Patient Characteristics

Several patient characteristics are associated with higher odds of bleeding during anticoagulation therapy.\textsuperscript{134,135,140,144,275,277,317–324} The patient factor most consistently predictive of major bleeding is a history of bleeding (especially GI bleeding).\textsuperscript{140,144,277} Other factors associated with a higher risk of bleeding include a history of stroke and the presence of a serious comorbid condition, such as renal insufficiency, anemia, or hypertension.\textsuperscript{134,135,140,144,277,317–324}

The relationship between older age and anticoagulant-associated bleeding has been controversial. Many older reports\textsuperscript{137,206,277,278,322–332} indicate that older individuals do not have an increased risk for bleeding, whereas other reports\textsuperscript{139,140,179,275,276,318,333–335} have described such an association. The discrepancy may be explained partly by the wide range in the mean age of the patients enrolled in the various studies, the relative lack of representation in most studies of patients over 80 years of age, and the selection and survivorship biases in noninception cohort studies. When investigators attempt to separate the effect of age from comorbid conditions associated with age, some have concluded that age in and of itself is not a major independent risk factor;\textsuperscript{137,207,323,336} whereas others have found it to be an independent risk factor,\textsuperscript{136,139} even after controlling for the intensity of the anticoagulant effect. Some studies have suggested\textsuperscript{314,337} that older patients who have high-quality anticoagulation management, such as that provided by an AMS, have the same risk of bleeding as their younger counterparts. Last, the location of major bleeding may be a factor, and reasonable evidence\textsuperscript{137,139,338,339} suggests a real increase in intracranial hemorrhage in elderly patients. A recent meta-
<table>
<thead>
<tr>
<th>Study, yr</th>
<th>Study Design</th>
<th>No. of Patients/Total</th>
<th>Predominant Model of Management</th>
<th>TTR, %</th>
<th>Above Range, %</th>
<th>Below Range, %</th>
<th>Frequency of Monitoring</th>
<th>Method of Determining TTR</th>
<th>Major Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RCT, prospective cohort, and crossover studies assessing the model of anticoagulation management</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beyth et al,283 2000</td>
<td>RCT</td>
<td>162/325</td>
<td>UC</td>
<td>32</td>
<td>16</td>
<td>51</td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Honstotte et al,284 1996</td>
<td>RCT</td>
<td>75/150</td>
<td>UC</td>
<td>59</td>
<td></td>
<td></td>
<td>% in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Sawicki,285 1999</td>
<td>RCT</td>
<td>89/179</td>
<td>UC</td>
<td>34</td>
<td>16</td>
<td>50</td>
<td>Days in range</td>
<td>Valves</td>
<td></td>
</tr>
<tr>
<td>Kortke and Korfer,286 2001</td>
<td>RCT</td>
<td>118/262</td>
<td>UC</td>
<td>60.5</td>
<td>3.7</td>
<td>35.8</td>
<td>Days in range</td>
<td>Valves</td>
<td></td>
</tr>
<tr>
<td>Matchar et al,287 2002</td>
<td>RCT</td>
<td>106/221</td>
<td>UC</td>
<td>76</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>AF</td>
<td></td>
</tr>
<tr>
<td>Wilson et al,288 2003</td>
<td>RCT</td>
<td>221/320</td>
<td>UC</td>
<td>63.5–67.9</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>AF/valves</td>
<td></td>
</tr>
<tr>
<td>Gadisseur et al,289 2003</td>
<td>Prospective cohort</td>
<td>2745</td>
<td>AMS</td>
<td>68</td>
<td>6</td>
<td>26</td>
<td>15 d‡</td>
<td>Days in range</td>
<td>Mixed</td>
</tr>
<tr>
<td>Cromheecke et al,290 2000</td>
<td>Crossover</td>
<td>50</td>
<td>AMS</td>
<td>49</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Watzke et al,291 2000</td>
<td>RCT</td>
<td>53/102</td>
<td>AMS (high intensity)</td>
<td>80.1</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Watzke et al,291 2000</td>
<td>RCT</td>
<td>53/102</td>
<td>AMS (standard intensity)</td>
<td>68.9</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Wilson et al,292 2004</td>
<td>Prospective cohort</td>
<td>402</td>
<td>AMS</td>
<td>66</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Menendez-Jandula et al,293 2005</td>
<td>RCT</td>
<td>369/737</td>
<td>AMS</td>
<td>55.6</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Fitzmaurice et al,294 2002</td>
<td>RCT</td>
<td>250/617</td>
<td>AMS</td>
<td>68</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Beyth et al,295 2000</td>
<td>RCT</td>
<td>163/325</td>
<td>PST</td>
<td>56</td>
<td>14</td>
<td>30</td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Honstotte et al,296 1996</td>
<td>RCT</td>
<td>75/150</td>
<td>PSM</td>
<td>92</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Sawicki,297 1999</td>
<td>RCT</td>
<td>90/179</td>
<td>PSM</td>
<td>57</td>
<td>10</td>
<td>33</td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Kulinna et al,298 1999</td>
<td>Prospective cohort</td>
<td>100</td>
<td>PSM</td>
<td>85.6</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Heidinger et al,299 2000</td>
<td>Prospective cohort</td>
<td>1,375</td>
<td>PSM</td>
<td>69</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Cromheecke et al,300 2000</td>
<td>Crossover</td>
<td>50</td>
<td>PSM</td>
<td>55</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Watzke et al,301 2000</td>
<td>RCT</td>
<td>49/102</td>
<td>PSM (high intensity)</td>
<td>86.2</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Watzke et al,301 2000</td>
<td>RCT</td>
<td>49/102</td>
<td>PSM (standard intensity)</td>
<td>82.2</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Kortke and Korfer,302 2001</td>
<td>RCT</td>
<td>163/325</td>
<td>PST</td>
<td>78.3</td>
<td>2.9</td>
<td>18.8</td>
<td>Days in range</td>
<td>Valves</td>
<td></td>
</tr>
<tr>
<td>Gadisseur et al,303 2005</td>
<td>RCT</td>
<td>52/320</td>
<td>PST</td>
<td>66.9</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>Mixed</td>
<td></td>
</tr>
<tr>
<td>Gadisseur et al,304 2003</td>
<td>RCT</td>
<td>47/320</td>
<td>PSM</td>
<td>68.6</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>AF/valves</td>
<td></td>
</tr>
<tr>
<td>Menendez-Jandula et al,305 2005</td>
<td>RCT</td>
<td>368/737</td>
<td>PSM</td>
<td>58.6</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>AF</td>
<td></td>
</tr>
<tr>
<td>Fitzmaurice et al,306 2005</td>
<td>RCT</td>
<td>337/617</td>
<td></td>
<td>70</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>AFEvalves</td>
<td></td>
</tr>
<tr>
<td><strong>RCT of VKA effectiveness for various indications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smith et al,307 1990</td>
<td>RCT</td>
<td>90</td>
<td>HQDM</td>
<td>64–68</td>
<td>2–4</td>
<td>28–34</td>
<td>% in range and cross-section of files</td>
<td>DVT/PE</td>
<td></td>
</tr>
<tr>
<td>BAATAF,172 1990</td>
<td>RCT</td>
<td>90</td>
<td>HQDM</td>
<td>88</td>
<td>9</td>
<td>8</td>
<td>Every 3 wk</td>
<td>Days in range</td>
<td></td>
</tr>
<tr>
<td>SPAF I,174 1991</td>
<td>RCT</td>
<td>90</td>
<td>HQDM</td>
<td>71</td>
<td>5</td>
<td>23</td>
<td>At least once/noon</td>
<td>Days in range</td>
<td>AF</td>
</tr>
<tr>
<td>Connolly et al,308 1991</td>
<td>RCT</td>
<td>90</td>
<td>HQDM</td>
<td>44</td>
<td>16</td>
<td>40</td>
<td>Every 3 wk</td>
<td>Days in range</td>
<td>AF</td>
</tr>
<tr>
<td>Ezekowitz et al,309 1992</td>
<td>RCT</td>
<td>90</td>
<td>HQDM</td>
<td>56</td>
<td>15</td>
<td>29</td>
<td>Monthly</td>
<td>Days in range</td>
<td>AF</td>
</tr>
<tr>
<td>EAFT,175 1993</td>
<td>RCT</td>
<td>90</td>
<td>HQDM</td>
<td>59</td>
<td>9</td>
<td>32</td>
<td>Every 5 wk</td>
<td>Days in range</td>
<td>AF</td>
</tr>
<tr>
<td>Study, yr</td>
<td>Study Design</td>
<td>No. of Patients/Total</td>
<td>Predominant Model of Management</td>
<td>TTR, %</td>
<td>Above Range, %</td>
<td>Below Range, %</td>
<td>Frequency of Monitoring</td>
<td>Method of Determining TTR</td>
<td>Major Diagnosis</td>
</tr>
<tr>
<td>-----------</td>
<td>--------------</td>
<td>----------------------</td>
<td>-------------------------------</td>
<td>--------</td>
<td>---------------</td>
<td>---------------</td>
<td>------------------------</td>
<td>--------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>ASPECT,299 1994</td>
<td>RCT</td>
<td>HQDM</td>
<td>6.274</td>
<td>6.920</td>
<td>29</td>
<td>%</td>
<td>After MI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPAF II,300 1994</td>
<td>RCT</td>
<td>HQDM</td>
<td>74</td>
<td>5</td>
<td>21</td>
<td>At least once/no</td>
<td>AF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPAF III,301 1996</td>
<td>RCT</td>
<td>HQDM</td>
<td>61</td>
<td>14</td>
<td>25</td>
<td>At least once/no</td>
<td>AF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hellemons et al,302 1999</td>
<td>RCT</td>
<td>HQDM</td>
<td>48</td>
<td>24</td>
<td>25</td>
<td>Every 2–6</td>
<td>%</td>
<td>AF</td>
<td></td>
</tr>
<tr>
<td>Hutten et al,303 1999</td>
<td>RCT</td>
<td>HQDM</td>
<td>61</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>AF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gulløv et al,304 1998</td>
<td>RCT</td>
<td>HQDM (high dose)</td>
<td>73</td>
<td>9</td>
<td>18</td>
<td>Not &gt; q 4</td>
<td>Days in range</td>
<td>AF</td>
<td></td>
</tr>
<tr>
<td>Hurlen et al,305 2002</td>
<td>RCT</td>
<td>HQDM (low dose)</td>
<td>42</td>
<td>4</td>
<td>34</td>
<td>% in range</td>
<td>ACs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Butchart et al,306 2002</td>
<td>Prospective cohort</td>
<td>HQDM (high dose)</td>
<td>75.5</td>
<td>12.5</td>
<td>12</td>
<td>% in range</td>
<td>Valves</td>
<td></td>
<td></td>
</tr>
<tr>
<td>van Es et al,307 2002</td>
<td>RCT</td>
<td>HQDM (low dose)</td>
<td>~48</td>
<td>~17</td>
<td>~35</td>
<td>Days in range</td>
<td>AF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kearon et al,308 2003</td>
<td>RCT</td>
<td>HQDM</td>
<td>69</td>
<td>11</td>
<td>20</td>
<td>26 d</td>
<td>Days in range</td>
<td>AF</td>
<td></td>
</tr>
<tr>
<td>Chimowitz et al,304 2005</td>
<td>RCT</td>
<td>HQDM</td>
<td>63.1</td>
<td>17.4</td>
<td>22.7</td>
<td>Days in range</td>
<td>CNS ischemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACTIVE,309 2006</td>
<td>RCT</td>
<td>HQDM</td>
<td>63.8</td>
<td>15.4</td>
<td>20.8</td>
<td>Monthly</td>
<td>% in range</td>
<td>AF</td>
<td></td>
</tr>
<tr>
<td>SPORTIF III,310 2003</td>
<td>RCT</td>
<td>HQDM</td>
<td>66</td>
<td>NA</td>
<td>NA</td>
<td>Monthly</td>
<td>Days in range</td>
<td>AF</td>
<td></td>
</tr>
<tr>
<td>SPORTIF V,311 2005</td>
<td>RCT</td>
<td>HQDM</td>
<td>68</td>
<td>12</td>
<td>20</td>
<td>Monthly</td>
<td>Days in range</td>
<td>AF</td>
<td></td>
</tr>
<tr>
<td>Flessinger et al,312 2005</td>
<td>RCT</td>
<td>HQDM</td>
<td>61</td>
<td></td>
<td></td>
<td>Days in range</td>
<td>DVT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*ACS = acute coronary syndrome; AF = atrial fibrillation; HQDM = high-quality dose management; MI = myocardial infarct; PE = pulmonary embolus. See Table 4 for abbreviation not used in the text.
†Studies include those from 1990 or later that were prospective and where TTR and model of anticoagulation management were indicated.
‡Studies of VKA efficacy in various conditions are RCTs where TTR was indicated. The model of management is considered to be the equivalent of an AMS or HQDM.
§Used expanded therapeutic range.
3.3 Frequency of Hemorrhage

The rate of hemorrhagic events must be interpreted in the context of the characteristics of the group studied. Factors that influence the rate of bleeding include the following: the target INR range; whether patients are mostly new to therapy or are participating in established long-term therapy; whether an INR or PT is used to manage therapy; the indication for anticoagulation; the type of VKA used; patient-specific risk factors, including concomitant antiplatelet therapy; and the quality of dose management. It is also not appropriate to extrapolate the rates of adverse events from randomized controlled trials to everyday practice because high-risk patients may be excluded from clinical trials, and monitoring and management of anticoagulation often are more coordinated in clinical trials than in clinical practice. The frequency of hemorrhage associated with oral anticoagulant therapy is reviewed in detail in the “Hemorrhagic Complications” chapter in this supplement.

3.4 Nonhemorrhagic Adverse Events

Other than hemorrhage, the most important side effects of warfarin are acute thrombotic complications, such as skin necrosis and limb gangrene. These uncommon complications are usually observed on the third to eighth day of therapy and are caused by extensive thrombosis of the venules and capillaries within the subcutaneous fat (in the case of skin necrosis) and massive outflow obstruction of the venous circulation of the limb (in the case of limb gangrene). The pathogenesis of these complications and the reason for the localization of the lesions are not well-understood. An association between warfarin-induced skin necrosis and protein C deficiency and, less commonly, protein S deficiency has been reported, but this complication also occurs in nondeficient individuals. A pathogenic role for protein C deficiency is supported by the similarity of the lesions to those seen in neonatal purpura fulminans that complicate homozygous protein C deficiency. A variant of this syndrome also attributed to a severe, warfarin-induced depletion of protein C is the occurrence of venous limb gangrene during warfarin treatment of cancer-associated DVT and in some patients with heparin-induced thrombocytopenia started on warfarin after withdrawal of heparin. The management of patients with warfarin-induced skin necrosis who require lifelong anticoagulant therapy is problematic. Therapy with warfarin is considered to be contraindicated, and long-term heparin therapy is inconvenient and associated with osteoporosis. A reasonable approach in such patients is to restart warfarin therapy at a low dose (eg, 2 mg), under the coverage of therapeutic doses of heparin, and to gradually increase the warfarin dose over 1 or more weeks. This approach should avoid an abrupt fall in protein C levels before there is a reduction in the levels of factors II, IX, and X, and it has been reported to not be associated with the recurrence of skin necrosis in a number of case reports.

3.5 Management of Adverse Events

For the management of major bleeding in patients on VKA therapy, the reader is referred to the discussion under the section, Management of Nontherapeutic INRs With or Without Bleeding.

3.5.1 Alternative Treatment for the Patient Who Bleeds During Warfarin Therapy

The short-term management of patients who bleed with an excessively prolonged INR has been discussed above. The long-term management of patients who have unexplained or recurrent bleeding but who require ongoing protection against systemic embolism (eg, patients with mechanical heart valves...
or with atrial fibrillation and other risk factors) is problematic. Clinicians can consider the following two options: (1) attempt to identify and reverse the cause of bleeding and (2) examine the possibility of lowering the intensity of the anticoagulant effect. Every effort should be made to treat the cause of bleeding (eg, the use of aggressive antinucleic therapy) if it is potentially reversible or to use an antiplatelet agent for selected indications (see the "Antiplatelet Drugs" chapter in this supplement).

The risk of bleeding is strongly related to the intensity of the anticoagulant effect. Therefore, in patients who continue to bleed, the INR should be maintained at the lower limit of the therapeutic range (ie, 2.0). Laboratory control of treatment should be optimised by performing frequent INR measurements and by ensuring that a moderately responsive thromboplastin (ISI, < 1.7) is used. For patients with mechanical prosthetic valves (and a persisting risk of increased bleeding), it would be reasonable to aim for an INR of 2.0 to 2.5. Alternatively, in selected patients, one may consider valve replacement with a bioprosthetic valve. For patients with atrial fibrillation (and a persisting risk of increased bleeding), the anticoagulant intensity can be reduced to an INR of 1.5 to 2.0 with the expectation that efficacy will be reduced but not abolished. Alternatively, aspirin can be used to replace warfarin in patients with atrial fibrillation but, again, with the expectation of reduced efficacy. The decision to lower the intensity of therapy to avoid bleeding should be discussed with the patient to understand the patient’s preference and values with regard to the risk of thrombosis with lower-intensity therapy and the risk of bleeding with standard therapeutic intensity.

### 3.5.2 Diagnostic Evaluation of Bleeding

When bleeding occurs, especially from the GI or urinary tract, the presence of an underlying occult lesion should be considered. A number of descriptive studies have reported on the probability of finding such a lesion. Coon and Willis identified occult lesions that were responsible for bleeding in 11% of 292 patients with hemorrhage. Jaffin et al found a 12% prevalence of positive stool occult blood test results in 175 patients receiving warfarin or heparin compared with 3% in 74 control subjects. There was no difference between the mean PT or activated partial thromboplastin time in patients with positive and negative test results. In the 16 patients with positive stool occult blood test results, 15 had a lesion that had not been previously suspected, and 4 patients had neoplastic disease. Landefeld et al found that 14 of 41 patients with GI bleeding had important remediable lesions of which two were malignant. This limited information supports the need to investigate patients with occult GI bleeding, as it may herald the presence of an underlying malignancy.

In a randomized controlled study, Culclasure et al found microscopic hematuria in 3.2% of patients (n = 243) receiving oral anticoagulation therapy compared to 4.8% in the control group (n = 258) not receiving anticoagulant therapy. There was no difference in the rate of hematuria with therapeutic or high INRs. Following a second episode of hematuria, 43 patients (patients receiving anticoagulation therapy, n = 32; control patients, n = 11) were investigated. Of these patients, 27 receiving anticoagulation therapy (84%) and 8 controls (73%) were found to have significant underlying disease, with three cancers found in the combined group (7%). These findings are in contrast to the results of other case series that have reported a higher incidence of underlying lesions in patients who develop hematuria while receiving anticoagulant therapy.

### 4.0 Models of Anticoagulation Management

The effectiveness and safety of VKAs critically depend on maintaining the INR in the therapeutic range. This objective is facilitated by aiming for an INR that is in the middle of the INR range (ie, a goal of 2.5 for a designated range of 2.0 to 3.0 and a goal of 3.0 for a designated range of 2.5 to 3.5). Approaches to improve anticoagulant control include the use of (1) AMS (ie, anticoagulation clinics) to manage therapy, (2) POC INR testing that allows PST and PSM of dose adjustments, and (3) computer software programs to aid in dose adjustment.

### 4.1 Optimal Management of VKA Therapy

The results of many nonrandomized, retrospective studies have reported better outcomes in patients when anticoagulant therapy is managed by an AMS or ACC than by their personal physicians (ie, UC). Four such studies of UC have reported major hemorrhagic rates ranging from 2.8 to 8.1% per patient-year of therapy. Rates of thromboembolism were not reported except in two studies in which the event rates were 6.2% and 8.1% per patient-year (Table 7). Similarly, retrospective and prospective cohort studies of care provided by an AMS reported rates of major hemorrhage or thrombosis ranging from 1.4 to 3.3% and 0.7 to 6.3% per patient-year of therapy, respectively (Table 7). Three retrospective comparative studies using a before-and-after design of patients managed by UC or an AMS reported signifi-
### Table 7—Retrospective and Prospective Trials of UC or AMS Management Reporting Major Hemorrhage/Thromboembolism*

<table>
<thead>
<tr>
<th>Study, yr</th>
<th>Type of Patient</th>
<th>Indication</th>
<th>Intervention</th>
<th>Patients Analyzed, No.</th>
<th>Follow-up, Patient-yr</th>
<th>Major Hemorrhage, %</th>
<th>RR (95% CI)</th>
<th>Recurrent TE, %</th>
<th>RR (95% CI)</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UC: retrospective trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gitter et al,195 1995</td>
<td>Noninception cohort</td>
<td>Mixed</td>
<td>UC</td>
<td>261</td>
<td>221</td>
<td>8.1</td>
<td>8.1</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beyth et al,197 1998</td>
<td>Inception cohort</td>
<td>Mixed</td>
<td>UC</td>
<td>264</td>
<td>440</td>
<td>5.0</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steffensen et al,198 1997</td>
<td>Inception cohort</td>
<td>Mixed</td>
<td>UC</td>
<td>682</td>
<td>756</td>
<td>6.0</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Willey et al,199 2004</td>
<td>Inception cohort</td>
<td>VTE</td>
<td>UC</td>
<td>2,090</td>
<td>1,441</td>
<td>2.5</td>
<td>6.2</td>
<td>6.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AMS: retrospective trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>van der Meer et al,200 1993</td>
<td>Noninception cohort</td>
<td>Mixed</td>
<td>AMS</td>
<td>6,814</td>
<td>6,085</td>
<td>3.3</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannegeiter et al,201 1995</td>
<td>Noninception cohort</td>
<td>MHV</td>
<td>AMS</td>
<td>1,608</td>
<td>6,475</td>
<td>2.5</td>
<td>0.7</td>
<td>0.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Veeger et al,202 2005</td>
<td>Inception cohort</td>
<td>VTE</td>
<td>AMS</td>
<td>2,304</td>
<td>1,441</td>
<td>2.8</td>
<td>6.3</td>
<td>6.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AMS: prospective</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palareti et al,203,204 1996</td>
<td>Inception cohort</td>
<td>Mixed</td>
<td>AMS</td>
<td>2,745</td>
<td>2,011</td>
<td>1.4</td>
<td>3.5</td>
<td>3.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdelhafiz and Wheeldon,205 2004</td>
<td>Inception cohort</td>
<td>AF</td>
<td>AMS</td>
<td>402</td>
<td>636</td>
<td>1.7</td>
<td>1.5</td>
<td>1.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>UC vs AMS: retrospective trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Costelazzo et al,206 1993</td>
<td>NA</td>
<td>MHV</td>
<td>UC</td>
<td>271</td>
<td>677</td>
<td>4.7</td>
<td>6.6</td>
<td>6.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NA</td>
<td>MHV</td>
<td>AMS</td>
<td>271</td>
<td>669</td>
<td>1</td>
<td>0.6</td>
<td>0.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(p &lt; 0.01)</td>
<td>(p &lt; 0.01)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chiquette et al,207 1998</td>
<td>NA</td>
<td>Mixed</td>
<td>UC</td>
<td>142</td>
<td>102</td>
<td>3.9</td>
<td>11.8</td>
<td>Cost savings of AMS vs UC of $1,621/patient-yr</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NA</td>
<td>Mixed</td>
<td>AMS</td>
<td>82</td>
<td>199</td>
<td>1.6</td>
<td>3.3</td>
<td>3.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(p &lt; 0.5)</td>
<td>(p &lt; 0.05)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Witt et al,208 2005</td>
<td>NA</td>
<td>Mixed</td>
<td>UC</td>
<td>3,322</td>
<td>1,661</td>
<td>2.2</td>
<td>3.0</td>
<td>3.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NA</td>
<td>Mixed</td>
<td>AMS</td>
<td>3,323</td>
<td>1,661</td>
<td>2.1</td>
<td>1.2</td>
<td>1.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(p = NS)</td>
<td>(p &lt; 0.05)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.95 (0.57,1.60)</td>
<td>0.40 (0.22,0.71)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>UC vs AMS: randomized trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matcher et al,209 2002</td>
<td>Inception cohort</td>
<td>AF</td>
<td>UC</td>
<td>190</td>
<td>NA</td>
<td>1.6</td>
<td>7.4</td>
<td>7.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inception cohort</td>
<td>AF</td>
<td>AMS</td>
<td>173</td>
<td>NA</td>
<td>1.7</td>
<td>5.2</td>
<td>5.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.10 (0.22–5.37)</td>
<td>0.71 (0.31–1.59)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wilson et al,210 2003</td>
<td>Inception cohort</td>
<td>Mixed</td>
<td>UC</td>
<td>106</td>
<td>109</td>
<td>0.9</td>
<td>1.8</td>
<td>1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inception cohort</td>
<td>Mixed</td>
<td>AMS</td>
<td>112</td>
<td>112</td>
<td>1.8</td>
<td>0.9</td>
<td>0.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.95 (0.18–21.16)</td>
<td>0.63 (0.44–0.92)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*MHV = mechanical heart valve; NA = not applicable; NS = not significant; VTE = venous thromboembolism; RR = relative risk; TE = thromboembolism.
cant improvements in outcomes of hemorrhage or thrombosis with AMS-directed care (Table 7). In contrast, however, two prospective, randomized controlled trials, comparing UC with the care of an AMS failed to show a significant difference in major hemorrhage or thromboembolism (Table 7). The study by Matchar et al also failed to show a significant improvement in TTR between the two models of care, although the AMS performed modestly better than UC. Wilson et al observed a significant improvement in TTR in the AMS group compared to the UC group (82% vs 76%, respectively; p = 0.034). They also noted more high-risk INRs in the UC group vs the AMS group (40% vs 30%; p = 0.005). This latter study had a major limitation in that all patients were initially managed in an AMS for 3 months until they were stable and then were observed only for 3 months after randomization to either receive UC or to continue care by the AMS. The other study suffered from a high turnover of patients, the possibility of selection bias of those patients referred to the AMS, the open nature of the study, and targeted ranges that were sometimes outside of recommended guidelines.

Finally, in a systematic review of 67 studies representing more than 50,000 patients managed by anticoagulation clinics (68%), clinical trials (7%), or community practices (24%), van Walraven et al found that the practice setting had the greatest effect on anticoagulation control. TTR (days) varied from 56.7% in community practices to 66.4% for randomized trials. Compared to randomized trials the absolute reduction of TTR for community practices was −12.2% (95% CI −19.5% to −4.8%). The difference between community practices and anticoagulation clinics was −8.3% (95% CI −4.4% to −12.1%). Although the literature comparing UC and AMS is not as robust as one would like, and there is great heterogeneity between studies, the results are almost always consistent, indicating that care provided by an AMS results in better outcomes or more stable therapy than UC.

Recommendation

4.1.1. For health-care providers who manage oral anticoagulation therapy, we recommend that they do so in a systematic and coordinated fashion, incorporating patient education, systematic INR testing, tracking, follow-up, and good patient communication of results and dosing decisions as occurs in an AMS (Grade 1B).

4.2 POC INR Testing

Technological advances in POC PT measurement offer the potential for both simplifying and improving oral anticoagulation management in the professional setting as well as at home. POC monitors measure a thromboplastin-mediated clotting time from a fingerstick sample of capillary whole blood or from unanticoagulated venous whole blood. The result is then converted to a plasma PT equivalent by a microprocessor and is expressed as a PT or an INR. Each manufacturer typically establishes the conversion formula by simultaneously comparing fingerstick or venous whole blood results with an established laboratory method and reagent that is traceable to the international reference thromboplastin.

Numerous studies have reported on the accuracy and precision of these instruments, on the ability of both adult and child patients to obtain an INR, and on their general suitability for monitoring anticoagulant therapy. However, limitations to their accuracy and precision also have been documented. Problems identified with POC instruments include greater differences compared to a standard plasma-based methodology as INRs increase above the therapeutic range, incorrect calibration of the ISI of the POC instruments, the inability to calculate a mean normal PT, and inaccuracies in INR determination in patients with antiphospholipid antibodies with certain instruments. A major problem of comparative studies is that a similar lack of correlation of INR results exists when anticoagulated plasmas are simultaneously compared using different instrument/thromboplastin combinations. These differences may be clinically important in that they may lead to different dosing decisions.

Kaatz et al compared two POC monitors and four clinical laboratories against a secondary reference thromboplastin preparation. They found that laboratories using a more sensitive thromboplastin showed close agreement with the standard, whereas laboratories using an insensitive thromboplastin showed poor agreement. The two monitors fell between these two extremes.

Steps are still needed to ensure the conformity of POC PT monitors to the WHO INR PT standardization scheme, but the WHO ISI calibration procedure is not practicable using the monitors. Simpler procedures for ISI calibration of POC monitors have recently been tested in a number of multicenter sites by the European Concerted Action on Anticoagulation and the UK National External Quality Assessment Schemes. By using lyophilized plasma calibrants with independently certified INRs, Poller et al have shown that verification or recalibration of the ISI of the instrument is possible. However, to obtain reliable ISI values for the two instruments tested, they had to develop different ISI calibration methods. It is likely, therefore, that different types of POC monitor systems will require different ISI calibration methods. In a study of proficiency testing

Downloaded from chestjournal.org on July 6, 2008
Copyright © 2008 by American College of Chest Physicians
of three POC monitors over 6 years in more than 10 centers, Kitchen et al. found in each survey that INR results in 10 to 11% of the centers were > 15% different from results in other centers using the same monitors. This finding is compared to a 12% difference for hospitals using conventional INR techniques. Thus, as previously discussed, INR results from different instrument and reagent combinations, whether POC or conventional instruments, are not always equivalent. Although regular proficiency testing has been the standard for conventional laboratories and techniques, such testing is difficult at best and may not be possible with all POC instruments. Where possible, we suggest that personnel using POC office-based testing participate in proficiency schemes available through professional or national quality assurance organizations.

4.3 PST and PSM

PST or PSM using a POC instrument represents another model of care with the potential for improved outcomes as well as for greater convenience. PST or PSM is not a new concept, but it only became practical with the advent of POC instruments. Self-testing provides a convenient opportunity for increased frequency of testing when deemed necessary. The use of the same instrument provides a degree of consistency in instrumentation, and self-testing provides the potential for greater knowledge and awareness of therapy, possibly leading to improved compliance. Several systematic reviews or metaanalyses have been conducted in the past few years using different criteria for review, each showing improvements in either or both the quality of anticoagulation control (TTR) or adverse events.

In the most comprehensive metaanalysis, Heneghan et al. pooled estimates from 14 randomized trials of PST showing a significant reduction in thromboembolic events (OR, 0.45; 95% CI, 0.30 to 0.68), all-cause mortality (OR, 0.61; 95% CI, 0.38 to 0.98), and major hemorrhage (OR, 0.65; 95% CI, 0.42 to 0.99) vs the comparator. For PST and PSM combined, there were significant reductions in thromboembolic events (OR, 0.27; 95% CI, 0.12 to 0.59) and death (OR, 0.37; 95% CI, 0.16 to 0.85) but not major hemorrhage (OR, 0.93; 95% CI, 0.42 to 2.05). Table 8 summarizes the most pertinent prospective studies (randomized controlled trials) in which 50 or more patients were studied and clinical outcomes were reported as TTR, adverse events, or both. Both PST and PSM studies are included. Because the potential benefit of self-monitoring, either TTR or number of adverse events depends greatly on the quality of management of the comparator group, it is essential to characterize the control group, as in Table 8, according to whether the comparator arm is a UC model of management or an AMS. It should be noted that the difference between groups for TTR is considerably less marked when compared to an AMS as compared to UC, as one might expect given the previous discussion of the quality of anticoagulation control demonstrated in a UC model of management.

None of these PST studies were adequately designed to clearly answer the important questions of what might account for better therapeutic control. The major variables not adequately controlled for include the level of patient education, compliance, the frequency of monitoring, and the consistency of reagent and instrumentation use. Further studies are needed to define the importance of these variables; such studies are ongoing. PST and PSM also require special patient training to implement, and this mode of therapy may not be suitable for all patients. It is impractical to apply uniform proficiency testing to PST, but healthcare providers should assess patient and equipment performance periodically (eg, once or twice per year) using duplicate testing on both the patient’s instrument and an office-based instrument. As a consequence of potentially improving outcomes and avoiding adverse events, some investigators have also shown a significant cost savings for PSM as well as an improvement in quality of life.

Recommendation

4.3.1. PSM is a choice made by patients and health-care providers that depends on many factors. In patients who are suitably selected and trained, PST or PSM is an effective alternative treatment model. We suggest that such therapeutic management be implemented where suitable (Grade 2B).

4.4 Data Management and Computerized Dosing

An obstacle to the safety and effectiveness of warfarin therapy is the poor quality of dose management as currently practiced. Data from clinical trials and observational studies on the success of achieving TTR have indicated a wide range of success (Table 6), from a low of 33% for a UC model to 90% for PSM. Computer assistance through dedicated programs may improve dose management and TTR. Although programs differ, they typically calculate whether a dose adjustment is necessary from a user-defined table of trend rules for each therapeutic range. If it recommends dose adjustment, the current INR is compared to the target INR, and the difference in INR is used in a proprietary equation to calculate the new dose. The time to the next test also is set by the program using a set of variables comparing the current INR, the interval from the last test, the number of
<table>
<thead>
<tr>
<th>Author, yr</th>
<th>Study Design</th>
<th>Intervention</th>
<th>No. of Patients</th>
<th>Study Duration, mo</th>
<th>TTR, % INRs or Time in Range Major Hemorrhage</th>
<th>Thromboembolism</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>PST vs UC</em></td>
<td>Beyth et al, 2000</td>
<td>RCT</td>
<td>PST/AMS†; UC</td>
<td>163</td>
<td>6</td>
<td>56/32 p &lt; 0.001 12%</td>
<td>6 p = 0.049 8.6%</td>
</tr>
<tr>
<td><em>PST vs AMS</em></td>
<td>White et al, 1989</td>
<td>RCT</td>
<td>PST/AMS†; AMS</td>
<td>23</td>
<td>2</td>
<td>93/75 p = 0.003 0</td>
<td>0</td>
</tr>
<tr>
<td>Gadisseur et al, 2003</td>
<td>RCT</td>
<td>PST/AMS†; AMS</td>
<td>52</td>
<td>6</td>
<td>63.9/61.3 p = 0.14 0; 1 event</td>
<td>0</td>
<td>Mixed indications; differences in TTR were noted; betweenacenocoumarol group and phenprocoumon group</td>
</tr>
<tr>
<td>Kaatz et al, 2001</td>
<td>RCT</td>
<td>PST/AMS†; AMS</td>
<td>63</td>
<td>63 p = NS</td>
<td>0</td>
<td>1 event</td>
<td></td>
</tr>
<tr>
<td><em>PSM vs UC</em></td>
<td>Horst et al, 1996</td>
<td>RCT</td>
<td>PSM UC</td>
<td>75</td>
<td>18</td>
<td>92.4/58.8</td>
<td></td>
</tr>
<tr>
<td>Sawicki, 1999</td>
<td>RCT</td>
<td>PSM UC</td>
<td>83</td>
<td>3</td>
<td>57/33.8 p = 0.006 1 event</td>
<td>1 event</td>
<td>Mixed indications; At 6 mo TTR between groups; was NS (p = 0.22)</td>
</tr>
<tr>
<td>Fitzmaurice et al, 2002</td>
<td>RCT</td>
<td>PSM UC</td>
<td>23</td>
<td>6</td>
<td>74/77 p = NS 0</td>
<td>1 event</td>
<td>Mixed indications</td>
</tr>
<tr>
<td>Kortke and Korfer, 2001</td>
<td>RCT</td>
<td>PSM UC</td>
<td>305</td>
<td>24</td>
<td>78.3/60.5 p &lt; 0.001 1.7%</td>
<td>2.6% p = NS 1.2%</td>
<td>2.1% p = NS</td>
</tr>
<tr>
<td>Sidhu and O’Kane, 2001</td>
<td>RCT</td>
<td>PSM UC</td>
<td>34</td>
<td>24</td>
<td>76.5/63.8 p &lt; 0.0001 1 event</td>
<td>1 event</td>
<td>Mixed indication; one episode of traumatic bleeds in each group</td>
</tr>
<tr>
<td>Gadisseur et al, 2003</td>
<td>RCT</td>
<td>PSM AMS</td>
<td>47</td>
<td>6</td>
<td>66.3/63.9 p = 0.14 1 event</td>
<td>0</td>
<td>Indications: atrial fibrillation; study stopped early because of poor enrollment</td>
</tr>
<tr>
<td>Sunderji et al, 2004</td>
<td>RCT</td>
<td>PSM UC</td>
<td>69</td>
<td>8</td>
<td>71.8/63.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Volker et al, 2005</td>
<td>RCT</td>
<td>PSM UC</td>
<td>101</td>
<td>5</td>
<td>67.8/58.5 p = 0.0061 2 events</td>
<td>0</td>
<td>Indications: atrial fibrillation; study stopped early because of poor enrollment</td>
</tr>
<tr>
<td><em>PSM vs AMS</em></td>
<td>Watzke et al, 2000</td>
<td>RCT</td>
<td>PSM AMS</td>
<td>49</td>
<td>3</td>
<td>84.5/73.8</td>
<td>1 event</td>
</tr>
<tr>
<td>Khan et al, 2004</td>
<td>RCT</td>
<td>PSM AMS</td>
<td>40</td>
<td>6</td>
<td>71.1/70.4</td>
<td>0</td>
<td>1 event</td>
</tr>
<tr>
<td>Menendez-Jandula et al, 2005</td>
<td>RCT</td>
<td>PSM AMS</td>
<td>368</td>
<td>12</td>
<td>59.6/55.6 p = NS 4 events</td>
<td>7 events</td>
<td>Mixed indications; overall adverse event rate 2.2% in PSM vs 7.3% in AMS (95% CI 1.7–8.5)</td>
</tr>
</tbody>
</table>

*See Tables 4 and 7 for abbreviations not used in the text.
†An AMS performed the dose adjustments for the PST patients.
Computerized dose management (with specific software programs) is another option that has been shown to be at least equivalent to physician-managed dosing when large populations of patients are being managed. Similar to PSM, we think that computerized dose management is a physician preference based on a number of factors, such as panel size and ancillary help, and we have no recommendation.

ACKNOWLEDGMENT: We wish to acknowledge the important assistance of Ann Wittkowsky, Pharm D, in developing these guidelines.

**CONFLICT OF INTEREST DISCLOSURES**

Dr. Ansell discloses that he has received consultant fees from Bristol-Myers Squibb, Roche Diagnostics, and International Technidyne Corporation. He is also on the speakers bureau for Roche Diagnostic Corporation and Sanofi-Aventis, and is the past president of the Anticoagulation Forum.

Dr. Hirsh discloses that he has received partial support for writing two books, one on fondaparinux and one on low-molecular-weight heparin.

Dr. Jacobson discloses that he has received grant monies from the National Institutes of Health, the Department of Veterans Affairs, Sanofi, Boehringer Ingelheim, and Roche Diagnostics. He is on the speakers bureau for Bristol-Myers Squibb and GlaxoSmithKline. Dr. Jacobson has served on advisory committees for Roche Diagnostics and Sanofi. He has served in fiduciary positions for the Loma Linda Veterans Association for Research and Education, the Loma Linda University School of Medicine Alumni Association, and the Anticoagulation Forum.

Dr. Hylek discloses that she has received grant monies from AstraZeneca and Bristol-Myers Squibb, and that she has also served on an advisory committee for Bristol-Myers Squibb.

Dr. Crowther discloses that he received grant monies from the Heart and Stroke Foundation, the Canadian Institutes for Health Research, Leo Laboratories, Pfizer, and Sanofi-Aventis. He also received consultant fees from Leo Laboratories, Sanofi-Aventis, Bayer, and Pfizer. Dr. Crowther has served on the speakers bureau for Leo Laboratories, Pfizer, Bayer, and Organon, and is on an advisory committee for Bayer.

Dr. Palareti discloses that he serves on the speakers bureau of Sanofi-Aventis, GlaxoSmithKline, Instrumentation Laboratory of Roche Diagnostics, and Dade-Behring. He is a member of the Executive Committee of the Italian Federation of Anticoagulation Clinics and the Italian Society of Hematology and Thrombosis (ISTH), and is Co-chair of the Subcommittee on Control of Anticoagulation of the ISTH.

**REFERENCES**

4 Trivedi LS, Bhee M, Galvan JH, et al. Normal and warfarin-
44 Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation
52 Oldenburg J, Quenzel E-M, Harbrecht V, et al. Missence mutations at ALA-10 in the factor X propeptide: an insig
57 Oldenburg J, Quenzel E-M, Harbrecht V, et al. Missence mutations at ALA-10 in the factor X propeptide: an insig
58 O’Reilly RA, Trager WF. Stereoselective interaction of phenylbutazone with 13C/12C labelled racemates of warfa
68 Owens JC, Neely WB, Owen WR. Effect of sodium dextro
72 Bell WR. Acetaminophen and warfarin: undesirable synergy. JAMA 1989; 279:702–703
74 Thijssen HH, Soute BA, Vervoort LM, et al. Paracetamol (acetaminophen) warfarin interaction: nAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004; 92:797–802
75 Hylek EM. Paracetamol (acetaminophen) and warfarin inter
76 Weibert RT, Lorenz SM, Townsend RJ, et al. Effect of erythromycin in patients receiving long-term warfarin ther
78 Udall JA. Human sources and absorption of vitamin K in relation to anticoagulation. JAMA 1965; 194:127–129
83 Brown CH, Natelson EA, Bradowsh MW, et al. The hemo

www.chestjournal.org


110 Kirkwood TBL. Calibration of thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983; 49:238–244


115 Denson KWE, Reed SV, Haddon ME. Validity of the INR system for patients with liver impairment. Thromb Haemost 1995; 73:162–166

116 Robert A, Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology 1996; 24:1392–1394

117 Malinchoc M, Kamath PS. Normalizing the prothrombin time. Hepatology 2000; 32:581


122 Ray MJ, Smith IR. The dependence of the international sensitivity index on the coagulometer used to perform the prothrombin time. Thromb Haemost 1990; 63:424–429


127 Fairweather RB, Ansell J, van den Besselaar AM, et al.


129 Poller L. Laboratory control of oral anticoagulants [editorial]. BMJ 1987; 294:1184


133 Adcock DM, Kressen DC, Marlar RA. Effect of 3.2% vs. 3.8% sodium citrate on routine coagulation testing. Am J Clin Pathol 1997; 107:105–110


182 van Ex RF, Jonker JJC, Verheugt FWA, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomized controlled trial. Lancet 2002; 360:109–113


194 Ageno W, Turpie AGG, Steidl L, et al. Comparison of a daily fixed 2.5 mg warfarin dose with a 5 mg, International Normalized ratio adjusted, warfarin dose initially following heart valve replacement. Am J Cardiol 2001; 88:40–44


235 Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin

Copyright © 2008 by American College of Chest Physicians

www.chestjournal.org

CHEST / 133 / 6 / JUNE, 2008 SUPPLEMENT 193S

Downloaded from chestjournal.org on July 6, 2008


238 Cosgriff SW. The effectiveness of an oral vitamin K1 in controlling excessive hypoprothrombinemia during anticoagulant therapy. Ann Intern Med 1956; 45:12–22


251 Sconce E, Khan T, Mason J, et al. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005; 93:872–875


310 Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation...
313 Palareti G, Legnani C, Manotti C. The first months of oral anticoagulant treatment are associated with a very low quality of laboratory control: data from the Isoct Study [abstract]. Thromb Haemost 1999; 82(suppl):549
314 Hutten BA, Prins MH, Buller HR. Determinants of time spent in the therapeutic range while using vitamin k antagonists [abstract]. Thromb Haemost 1999; 82(suppl):545
382 Murray ET, Greaves M. INRs and point of care testing. BMJ 2003; 327:5–6
389 Poller L, Keown M, Chanhun N, et al. European concerted action on anticoagulation: multicentre international sensitivity index calibration of two types of point-of-care prothrom-


407 Muller E, Bergemann R. Economic analysis of bleeding and thromboembolic sequelae after heart valve replacement (GELIA 7): the GELIA Study Group. Eur Heart J 2001; 3(suppl):Q65–Q69


Jack Ansell, Jack Hirsh, Elaine Hylek, Alan Jacobson, Mark Crowther and Gualtiero Palareti
Chest 2008;133;160-198
DOI 10.1378/chest.08-0670

This information is current as of July 6, 2008

Updated Information & Services
Updated information and services, including high-resolution figures, can be found at:
http://chestjournal.org/cgi/content/full/133/6_suppl/160S

References
This article cites 412 articles, 130 of which you can access for free at:
http://chestjournal.org/cgi/content/full/133/6_suppl/160S#BIBL

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://chestjournal.org/misc/reprints.shtml

Reprints
Information about ordering reprints can be found online:
http://chestjournal.org/misc/reprints.shtml

Email alerting service
Receive free email alerts when new articles cite this article sign up in the box at the top right corner of the online article.

Images in PowerPoint format
Figures that appear in CHEST articles can be downloaded for teaching purposes in PowerPoint slide format. See any online article figure for directions.